Systems, apparatuses, and methods for detecting ectopic electrocardiogram signals during pulsed electric field ablation

Information

  • Patent Grant
  • 10688305
  • Patent Number
    10,688,305
  • Date Filed
    Monday, January 13, 2020
    4 years ago
  • Date Issued
    Tuesday, June 23, 2020
    4 years ago
  • Inventors
  • Original Assignees
    • Farapulse, Inc. (Menlo Park, CA, US)
  • Examiners
    • Mahmood; Nadia A
    Agents
    • Cooley LLP
Abstract
Systems, apparatus, and methods for ablation therapy are described herein, with a processor for confirming pacing capture or detecting ectopic beats. An apparatus includes a processor for receiving cardiac signal data captured by a set of electrodes, extracting a sliding window of the cardiac signal data, identifying a peak frequency over a subrange of frequencies associated with the extracted sliding window, detecting ectopic activity based at least on a measure of the peak frequency over the subrange of frequencies, in response to detecting ectopic activity, sending an indication of ectopic activity to a signal generator configured to generate pulsed waveforms for cardiac ablation such that the signal generator is deactivated or switched off from generating the pulsed waveforms. An apparatus can further include a processor for confirming pacing capture of the set of pacing pulses based on cardiac signal data.
Description
BACKGROUND

Application of brief ultra-short high voltage pulses to tissue may generate high electric fields in tissue to generate a local region of ablated tissue by the biophysical mechanism of irreversible electroporation.


In cardiac applications, high voltage pulses, however, may cause complications such as induced arrhythmias (e.g., ventricular fibrillation) if delivered during certain periods of cardiac activity. Accordingly, it can be desirable to delivery high voltage pulses for pulsed electric field ablation in synchrony with the cardiac cycle so as to avoid the risk of such complications,





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 is a block diagram of a system, according to embodiments.



FIG. 2 is a schematic cross-sectional illustration of an ablation catheter and a pacing catheter disposed in a heart, according to embodiments.



FIGS. 3A and 3B are schematic illustrations of a time sequence of electrocardiograms and cardiac pacing signals, according to embodiments.



FIG. 4 schematically depicts a device for generating pulsed electric field ablation, according to embodiments.



FIG. 5 depicts components of a device for detecting cardiac activity, according to embodiments.



FIG. 6 illustrates a method for tissue ablation, according to embodiments.



FIG. 7 illustrates a method for detecting ectopic cardiac activity, according to embodiments.



FIG. 8 illustrates a method for tissue ablation, according to embodiments.



FIG. 9 illustrates a method for detecting ectopic cardiac activity, according to embodiments.



FIG. 10 illustrates a method for detecting ectopic cardiac activity and confirming pacing capture, according to embodiments.





DETAILED DESCRIPTION

Described herein are systems, devices, and methods for detecting ectopic cardiac activity in connection with delivery of ablation energy to tissue such as pulsed electric field ablation. Pulsed electric field ablation uses ultra-short high-voltage pulses to generate large electric fields at desired regions of interest to generate a local region of ablated tissue via irreversible electroporation. In certain applications, including cardiac applications, it can be desirable to generate pulses for pulsed electric field ablation in synchronicity with a cardiac cycle. Synchronizing ablation energy delivery with the cardiac cycle may reduce the risk of induced arrhythmias such as atrial and/or ventricular fibrillation. One method of synchronizing delivery of pulses can be to pace of stimulate one or more cardiac cambers with periodic pacing signals with a predefined time period. For example, a cardiac stimulator may be used to deliver pacing pulses to one or more cardiac chambers such that the cardiac rhythm of a patient synchronizes with the pacing pulse. In some embodiments, pacing pulses can be delivered to the cardiac chamber(s) via an intracardiac catheter that is suitably positioned in the chamber(s). The intracardiac catheter can include one or more electrodes that are used to conduct the pacing signal into the heart. For example, the catheter can have a pair of electrodes (e.g., a most distal electrode and an electrode proximal to the distal electrode) that is used as a bipolar pair to deliver a pacing signal, with the two electrodes providing the forward and return current paths for the pacing signal. The pacing pulse can cause the cardiac chamber to generate its electrocardiogram (ECG) pulses in synchrony with the pacing pulses, thereby controlling the timing of the cardiac cycle.


Once the periodicity of the cardiac cycle is established and confirmed, e.g., by a physician, the delivery of high voltage ablation pulses can be timed to start in synchrony with the pacing signals. For example, the ablation pulses can be delivered with predetermined offsets from the pacing signals such that their delivery falls within the refractory window following the QRS waveform of the cardiac cycle. In some embodiments, the ablation pulses can be delivered to a cardiac chamber using an ablation catheter configured for pulsed electric field ablation.


While a cardiac chamber is being paced, however, localized electrical activity (e.g., pre-ventricular contraction (PVC)) may trigger ectopic cardiac activity that generates an additional localized T-wave (e.g., ectopic beat) that may overlap the next pacing pulse. Ablation energy delivered during these localized T-waves may have a high risk of inducing fibrillation.


Accordingly, it can be desirable to detect such localized or ectopic ECG activity that can occur between successive pacing pulses during ablation, such that the ablation system can ensure that ablation is not delivered during those times. For example, an ablation device can be configured to be disconnected from a signal generator when ectopic activity has been detected. By disconnecting or switching off the ablation device (for example, with a suitable relay), the risk of inducing a fibrillation event can be reduced.


Systems, devices, and methods described herein can be configured to detect ectopic signals and to control the operation of an ablation device based on such detection. For example, a system as described herein may include a cardiac stimulator and pacing device used to electrically pace the heart and ensure pacing capture to establish periodicity and predictability of the cardiac cycle. The pacing device may be configured to measure electrical cardiac activity (e.g., an electrocardiogram (ECG) signal) used to confirm pacing capture and/or detect ectopic cardiac activity. For example, predetermined portions of an ECG signal may be analyzed for an ectopic beat and synchronization between a pacing pulse and cardiac cycle. A cardiac activity status may be output to indicate the status of pacing capture and/or ectopic cardiac activity, and be used to control delivery of ablation energy to tissue.


The system may further include a signal generator and a processor configured to apply one or more voltage pulse waveforms to a selected set of electrodes of an ablation device to deliver energy to a region of interest (e.g., ablation energy for a set of tissue in a pulmonary vein ostium). The pulse waveforms disclosed herein may aid in therapeutic treatment of a variety of cardiac arrhythmias (e.g., atrial fibrillation).


The cardiac stimulator may synchronize the generation of the pulse waveform to a paced heartbeat in order to reduce unintended tissue damage. For example, a time window within a refractory period of the periodic cardiac cycle may be selected for voltage pulse waveform delivery. Thus, voltage pulse waveforms may be delivered in the refractory period of the cardiac cycle so as to avoid disruption of the sinus rhythm of the heart. The pulse waveform may be generated based on a cardiac activity status indicating an absence of an ectopic beat and confirmation of pacing capture. For example, the pulse waveform may be generated in synchronization with a pacing signal of the heart to avoid disruption of the sinus rhythm of the heart, and can be delivered outside of periods of detected ectopic activity. The pulse waveform can be delivered to one or more electrodes of one or more catheters that are epicardially or endocardially placed around the heart, such that those electrodes generate a pulsed electric field to ablate tissue. In some embodiments, the pulse waveform may include hierarchical waveforms to aid in tissue ablation and reduce damage to healthy tissue.


In some embodiments, an apparatus includes a memory and a processor operatively coupled to the memory. The processor can be configured to receive cardiac signal data captured by a set of electrodes; extract a sliding window of the cardiac signal data; identify a peak frequency over a subrange of frequencies associated with the extracted sliding window; detect ectopic activity based at least on a measure of the peak frequency over the subrange of frequencies; and in response to detecting ectopic activity, send an indication of ectopic activity to a signal generator configured to generate pulsed waveforms for cardiac ablation such that the signal generator is deactivated or switched off from generating the pulsed waveforms.


In some embodiments, an apparatus includes a memory and a processor operatively coupled to the memory. The processor can be configured to receive cardiac signal data captured by a set of electrodes; receive an indication of delivery of a set of pacing pulses to the cardiac tissue; extract portions of the cardiac signal data following delivery of a subset of successive pacing pulses from the set of pacing pulses; calculate, for each extracted portion, a set of moments of a function associated with that extracted portion; confirm pacing capture of the set of pacing pulses based at least on the set of moments calculated for each extracted portion; and in response to confirming pacing capture, send an indication of pacing capture to a signal generator configured to generate pulsed waveforms for cardiac ablation such that the signal generator is activated for generating the pulsed waveforms. In some embodiments, the processor is further configured to: analyze local peak frequencies of the cardiac signal data to detect ectopic activity; and in response to detecting ectopic activity, send an indication of ectopic activity to the signal generator such that the signal generator is switched off from generating the pulsed waveforms.


In some embodiments, a system includes a first controller configured to generate a pulsed waveform and deliver the pulsed waveform in synchrony with a set of pacing pulses to an ablation device; and a second controller operatively coupled to the first controller, the second controller configured to: generate the set of pacing pulses and deliver the set of pacing pulses to a pacing device; receive cardiac signal data captured by a set of electrodes; confirm pacing capture of the set of pacing pulses based on the cardiac signal data; and in response to confirming pacing capture, send an indication of pacing capture to the first controller to activate generation of the pulsed waveform. In some embodiments, the second controller is further configured to: monitor the cardiac signal data for ectopic activity; and when ectopic activity is present, send an indication of ectopic activity to the first controller to switch off generation of the pulsed waveform.


In some embodiments, a method includes receiving cardiac signal data captured by a set of electrodes disposed near cardiac tissue; extracting a sliding window of the cardiac signal data; identifying a peak frequency over a subrange of frequencies associated with the extracted sliding window; detecting ectopic activity based at least on a measure of the peak frequency over the subrange of frequencies; and in response to detecting ectopic activity, sending an indication of ectopic activity to a signal generator configured to generate pulsed waveforms for cardiac ablation such that the signal generator is switch off from generating the pulsed waveforms. The method can further include confirming pacing capture of the set of pacing pulses based on the cardiac signal data.


The term “electroporation” as used herein refers to the application of an electric field to a cell membrane to change the permeability of the cell membrane to the extracellular environment. The term “reversible electroporation” as used herein refers to the application of an electric field to a cell membrane to temporarily change the permeability of the cell membrane to the extracellular environment. For example, a cell undergoing reversible electroporation can observe the temporary and/or intermittent formation of one or more pores in its cell membrane that close up upon removal of the electric field. The term “irreversible electroporation” as used herein refers to the application of an electric field to a cell membrane to permanently change the permeability of the cell membrane to the extracellular environment. For example, a cell undergoing irreversible electroporation can observe the formation of one or more pores in its cell membrane that persist upon removal of the electric field.


Pulse waveforms for electroporation energy delivery as disclosed herein may enhance the safety, efficiency and effectiveness of energy delivery to tissue by reducing the electric field threshold associated with irreversible electroporation, thus yielding more effective ablative lesions with a reduction in total energy delivered. In some embodiments, the voltage pulse waveforms disclosed herein may be hierarchical and have a nested structure. For example, the pulse waveform may include hierarchical groupings of pulses having associated timescales. In some embodiments, the methods, systems, and devices disclosed herein may comprise one or more of the methods, systems, and devices described in International Application Serial No. PCT/US2019/014226, filed on Jan. 18, 2019, published as International Publication No. WO/2019/143960 on Jul. 25, 2019, and titled “SYSTEMS, DEVICES AND METHODS FOR FOCAL ABLATION,” the contents of which are hereby incorporated by reference in its entirety.


Systems

Disclosed herein are systems and devices configured for monitoring ectopic cardiac activity in connection with tissue ablation via the selective and rapid application of voltage pulse waveforms resulting in irreversible electroporation. Generally, a system for ablating tissue described here may include a cardiac stimulator for generating a pacing signal delivered by a pacing device to the heart. The system further measures electrical cardiac activity for identification of ectopic beats and/or to confirm pacing capture of the heart. The detected pacing signal and/or detected cardiac activity can be used to control delivery of a pulse waveform generated by a signal generator to an ablation device having one or more electrodes. As described herein, the systems and devices may be deployed epicardially and/or endocardially to treat heart conditions such as, for example, atrial fibrillation. Voltages may be applied to a selected subset of the electrodes, with independent subset selections for anode and cathode electrode selections.


Generally, the systems and devices described herein include one or more devices (e.g., catheters) configured to ablate tissue in a left atrial chamber of a heart. FIG. 1 illustrates a system (100) configured to deliver voltage pulse waveforms. The system (100) may include an apparatus (120) including one or more processor(s) or controller(s) (124) and a memory (126). The processor(s) (124) can function as, be integrated into, and/or control a signal generator (122) and/or a cardiac stimulator (128).


Each of the one or more processor(s) (124) may be any suitable processing device configured to run and/or execute a set of instructions or code. The processor may be, for example, a general purpose processor, a Field Programmable Gate Array (FPGA), an Application Specific Integrated Circuit (ASIC), a Digital Signal Processor (DSP), and/or the like. The processor may be configured to run and/or execute application processes and/or other modules, processes and/or functions associated with the system and/or a network associated therewith (not shown). The underlying device technologies may be provided in a variety of component types, e.g., metal-oxide semiconductor field-effect transistor (MOSFET) technologies like complementary metal-oxide semiconductor (CMOS), bipolar technologies like emitter-coupled logic (ECL), polymer technologies (e.g., silicon-conjugated polymer and metal-conjugated polymer-metal structures), mixed analog and digital, and/or the like.


The memory (126) may include a database (not shown) and may be, for example, a random access memory (RAM), a memory buffer, a hard drive, an erasable programmable read-only memory (EPROM), an electrically erasable read-only memory (EEPROM), a read-only memory (ROM), Flash memory, etc. The memory (126) may store instructions to cause the processor (124) to execute modules, processes and/or functions associated with the system (100), such as pulse waveform generation and/or cardiac pacing.


The apparatus (120) may be coupled to an ablation device (110) and/or a pacing device (130). When coupled to the ablation device (110) and pacing device (130), one or more components of the apparatus (120) (e.g., a processor (124) functioning as a signal generator (122) and/or cardiac stimulator (128)) can be in electrical communication with the ablation device (110) and/or pacing device (130) to control delivery of pacing signals, ablation signals, etc. via the ablation device (110) and pacing device (130) and/or to receive data (e.g., sensed signals) from the ablation device (110) and pacing device (130). If apparatus (120) includes multiple processors (124), one or more of the processor(s) (124) can communicate with one another to control pacing and/or ablation. The apparatus (120) can also include an input/output device (127) that enables the apparatus (120) to interface with other devices (e.g., ablation device (110) and/or pacing device (130)) and/or a user. For example, the apparatus (120) can include a user interface, e.g., a display, an audio device, etc. that enables presentation of outputs to a user and/or receipt of input from the user.


The signal generator (122) may be configured to generate ablation pulse waveforms for irreversible electroporation of tissue, such as, for example, pulmonary vein ostia. For example, the signal generator (122) may be a voltage pulse waveform generator and deliver a pulse waveform to the ablation device (110). The processor (124) may incorporate data received from memory (126), cardiac stimulator (128), and pacing device (130) to determine the parameters (e.g., timing, amplitude, width, duty cycle, etc.) of the pulse waveform to be generated by the signal generator (122). The memory (126) may further store instructions to cause the signal generator (122) to execute modules, processes and/or functions associated with the system (100), such as ectopic cardiac activity detection, pulse waveform generation, and/or cardiac pacing synchronization. For example, the memory (126) may be configured to store one or more of cardiac activity data, pulse waveform, and heart pacing data.


The pacing device (130) disposed in the patient may be configured to receive a heart pacing signal generated by the cardiac stimulator (128) of the apparatus (120) for cardiac stimulation. An indication of the pacing signal may be transmitted by the cardiac stimulator (128) to the signal generator (122). Based on the pacing signal, an indication of a voltage pulse waveform may be selected, computed, and/or otherwise identified by the processor (124) and generated by the signal generator (122). In some embodiments, the signal generator (122) is configured to generate the pulse waveform based on a cardiac activity status where the pulse waveform is in synchronization with the indication of the pacing signal (e.g., within a common refractory window). For example, in some embodiments, the common refractory window may start substantially immediately following a ventricular pacing signal (or after a very small delay) and last for a duration of approximately 250 milliseconds (ms) or less thereafter. In such embodiments, an entire pulse waveform may be delivered within this duration.


In some embodiments, one or more intracardiac electrodes, e.g., of the pacing device (130) and/or ablation device (110), can be configured to sense signals within the heart and deliver those signals to one or more of the processor(s) 124. The one or more processor(s) 124 can analyze the sensed signals for ectopic activity and control operation of the signal generator (122) based on such analysis, as further described below.


The system (100) may be in communication with other devices (not shown) via, for example, one or more networks, each of which may be any type of network. A wireless network may refer to any type of digital network that is not connected by cables of any kind. However, a wireless network may connect to a wireline network in order to interface with the Internet, other carrier voice and data networks, business networks, and personal networks. A wireline network is typically carried over copper twisted pair, coaxial cable or fiber optic cables. There are many different types of wireline networks including, wide area networks (WAN), metropolitan area networks (MAN), local area networks (LAN), campus area networks (CAN), global area networks (GAN), like the Internet, and virtual private networks (VPN). Hereinafter, network refers to any combination of combined wireless, wireline, public and private data networks that are typically interconnected through the Internet, to provide a unified networking and information access solution. The system (100) may further comprise one or more output devices such as a display, audio device, touchscreen, combinations thereof, and the like.



FIG. 2 is a schematic illustration of a heart (200), e.g., as seen from an anterior side (e.g., front of a subject) including an ablation device (220) and a pacing device (210) disposed therein, according to embodiments described herein. The pacing device (210) may be configured to measure cardiac activity and/or deliver pacing signal to the heart (200), and the ablation device (220) may be configured to receive and/or deliver a pulse waveform to cardiac tissue. As illustrated, in the anterior cross-section of the heart (200) depicted in FIG. 2, the dotted lines (201) schematically approximate the boundaries of the four heart chambers including the right ventricle RV (202) and left atrium LA (204). Pacing device (210) may be introduced into the right ventricle (202) and positioned such that it can stimulate the right ventricle (202) and obtain pacing capture. The pacing device (210) may comprise first electrode (212), second electrode (214), third electrode (216), and fourth electrode (218). The first electrode (212) and the second electrode (214) may be configured as a bipolar pair of pacing electrodes to pace the right ventricle (202). The pacing electrodes (212, 214) may be coupled to a cardiac stimulator (e.g., cardiac stimulator (128)). The third electrode (216) and the fourth electrode (218) may be configured as sensor elements to measure intracardiac activity (e.g., ECG signal) of the heart (200). While the pacing device (210) is described as being positioned in the right ventricle (202), it can be appreciated that the pacing device (210) can be positioned in other suitable sites. For example, the pacing device (210) can be placed in the coronary sinus, and a suitable electrode pair (e.g., electrodes (212, 214)) may be used to pace the ventricle.


The ablation device (220) may be introduced into an endocardial space of the left atrium (204) through an atrial septum via a trans-septal puncture. The distal portion of the ablation device (220) may include a set of electrodes (222, 224) configured to deliver ablation energy (e.g., pulse electric field energy) to tissue. In some embodiments, the electrodes (222, 224) of the ablation device (220) may be a set of independently addressable electrodes. Each electrode may include an insulated electrical lead configured to sustain a voltage potential of at least about 700 V without dielectric breakdown of its corresponding insulation. In some embodiments, the insulation on each of the electrical leads may sustain an electrical potential difference of between about 200 V to about 2,500 V across its thickness without dielectric breakdown. In some embodiments, the set of electrodes may include a plurality of electrodes. The plurality of electrodes may be grouped into one or more anode-cathode subsets such as, for example, a subset including one anode and one cathode, a subset including two anodes and two cathodes, a subset including two anodes and one cathode, a subset including one anode and two cathodes, a subset including three anodes and one cathode, a subset including three anodes and two cathodes, and/or the like. While two electrodes (222, 224) are depicted, it can be appreciated that ablation device (220) can include one or more additional electrodes, where one or more sets of electrodes can be configured with opposite polarities to deliver pulsed electric fields to ablate tissue.


The operation of systems and devices for detection of pacing signals and/or ectopic activity can be understood with reference to FIGS. 3A and 3B, which schematically illustrate a time series of periodic pacing pulses with cardiac activity, according to embodiments described herein.



FIG. 3A is a schematic illustration of a time sequence of an electrocardiogram (300) and cardiac pacing signal (310). The pacing signal (310) may comprise a set of periodic pacing pulses (312). For example, the pacing pulse (312) may comprise a rectangular pulse having a width of between about 1 ms and about 5 ms. In some embodiments, the pacing pulses (312) may be delivered using any of the pacing devices (e.g., pacing devices (130, 210)) described herein. For example, the pacing pulse (312) may be delivered via pacing electrodes (212, 214) of pacing catheter (210). In response to the pacing pulses (312), the cardiac cycle of the heart may synchronize with the pacing pulses (312). For example, the QRS waveforms (302) in FIG. 3A are synchronized with respective pacing pulses (312). The T-wave (304) that follows the QRS waveform (302) corresponds to the start of repolarization occurring in the cardiac myocytes. As such, delivery of an ablation pulse waveform after the T-wave begins may cause complications (e.g., atrial and/or ventricular fibrillation) and therefore be avoided. The time period (330) that starts from the onset of the pacing pulse (312) and ends before the T-wave (304) represents a safe time window during which an ablation pulsed electric field can be delivered to the heart. In some embodiments, ablation pulse waveforms are delivered within a refractory period (320) of the cardiac cycle following the pacing pulse (312). In some embodiments, more than one cardiac chamber may be paced (e.g., simultaneous pacing of an atrium and a ventricle) to establish a common refractory period for more than one cardiac chamber. In such embodiments, the pacing pulse (312) can be delivered during a common refractory period or overlap in the refractory period associated with each cardiac chamber.



FIG. 3B is a schematic illustration of a time sequence of an electrocardiogram (340) and cardiac pacing signal (350). Similar to the periodic pacing pulses (312) shown in FIG. 3A, each pacing pulse (352) may comprise a rectangular pulse having a width of between about 1 ms and about 5 ms, and may be delivered using any of the pacing devices (e.g., pacing devices (130, 210)) described herein. For example, the pacing pulse (352) may be delivered via pacing electrodes (212, 214) of pacing catheter (210). In response to the pacing pulses (352), the natural pacing function of the heart may synchronize with the QRS waveforms (342). The T-wave (344) that follows the QRS waveform (342) corresponds to the start of repolarization in the cardiac myocytes. Without ectopic activity, the time period (370) that starts from the onset of the pacing pulse (352) and ends before the T-wave (344) represents a safe time window during which an ablation pulsed electric field can be delivered to the heart. The electrocardiogram (340) includes a refractory period (360) during which ablation can be delivered. With ectopic activity, e.g., as represented by an ectopic pulse (380) in the electrocardiogram (340), delivery of pulsed electric field ablation during the time period (370) may induce fibrillation. As depicted in FIG. 3B, an ectopic pulse or complex (380) can precede the QRS waveform (342) synchronized with the pacing pulse (352). The ectopic pulse (380) may generate an ectopic T-wave (382) that precedes the T-wave (344) of the QRS waveform (342). If a pulse waveform is delivered during the period (328) following the ectopic pulse (380), the pulse waveform may overlap the ectopic T-wave (382) and thereby cause complications, e.g., by inducing fibrillation. Accordingly, it can be desirable to detect the occurrence of an ectopic complex such as ectopic pulse (380) during an ablation procedure (e.g., in real-time), and upon detection, interrupt delivery of pulsed electric field ablation pulses. As described in more detail herein, systems, devices, and methods described herein can enable ectopic beats to be detected in real-time (e.g., during a pacing and/or ablation process) and delivery of ablation energy to tissue to be controlled (e.g., interrupting delivery of pulse waveform pulses) in response thereto. For example, such systems, devices, and methods can be configured for automated detection of ectopic ECG activity such that, if an ectopic beat is detected, subsequent ablation delivery can be terminated, e.g., until a user has repositioned devices, adjusted pacing parameters, or made other clinical adjustments to obtain a ECG waveform in synchrony with pacing pulses that does not include ectopic activity.



FIG. 4 schematically depicts an example apparatus (903) for generating pulsed electric field energy for tissue ablation. The apparatus (903) can include components that are structurally and/or functionally similar to those of the apparatus (120), described above with reference to FIG. 1. In an embodiment, the apparatus (903) includes at least two controllers or processors (907, 908). The controller (907) can be configured to generate a waveform for pulsed electric field ablation via an ablation output (911) that connects to an energy delivery device such as, for example, an ablation catheter (e.g., ablation device (110)).


The controller (908) can be configured to generate a pacing stimulus and send that pacing stimulus to an intracardiac pacing catheter or similar medical device (e.g., pacing device (130)) via pacing output (920). The controller (908) can further send an indication (915) of the pacing stimulus to the controller (907), such that the delivery of the pulsed electric field energy can be synchronized with the cardiac pacing. The controllers (907, 908) can be operatively coupled to one another, e.g., by a communication bus (917). By synchronizing the delivery of the pulsed electric field ablation energy to the pacing stimulus, the apparatus (903) can ensure that pulsed electric field energy is delivery to sensitive anatomical structures (e.g., a cardiac chamber) during a refractory period, as described above, thereby avoiding the risk of inducing an arrhythmia such as a fibrillation event.


In some instances, an ectopic beat can arise by autonomous generation from a cardiac chamber. As described above, pulsed electric field ablation delivered during periods of ectopic activity can increase the risk of inducing an arrhythmia. Accordingly, it can be desirable to detect such ectopic activity. To detect such activity, cardiac signals (e.g., ECG recordings) from an intracardiac electrode pair can be sent as sensing signals (922) to the controller (908). The controller (908) can be configured to analyze the cardiac signals for ectopic beats. When the controller (908) detects an ectopic beat, the controller (908) can be configured to communicate with the controller (907) responsible for generating the ablation waveform, e.g., via communication bus (917), to halt the delivery of the pulsed electric field energy. For example, the controller (908) can send a signal to halt or interrupt ablation to the controller (907) in response to detecting ectopic activity.


In some embodiments, the apparatus (903) can be configured to confirm pacing capture prior to delivery of pulsed electric field energy. For example, the apparatus (903) via controller (908) can analyze the sensed cardiac signals (922) and communicate with controller (907) to deliver ablation upon confirmation of pacing capture. In some embodiments, the apparatus (903) can be equipped with a user interface for confirming pacing capture, e.g., via a manual input (927) by a user. For example, the apparatus (903) can include a display that displays the pacing signal and cardiac signal to allow a user to confirm pacing capture and indicate such confirmation to the apparatus (903) (e.g., by pushing a button on the user interface). In some embodiments, the apparatus (903) can analyze the sensed cardiac activity, and if such is found to not be in synchrony with the pacing stimulus, not perform ablation delivery and/or inform a user that pacing capture is absent (e.g., via user interface or a message). The user and/or apparatus (903) can then modify the pacing conditions, e.g., attempt pacing capture at a different rate, or move the pacing catheter to a location or position with better anatomical engagement.



FIG. 5 schematically depicts an example flow of a signal (e.g., an ECG signal) through one or more components of a controller, such as, for example, controller (908) depicted in FIG. 4, in more detail. As depicted, an incoming signal (1003) (e.g., raw analog cardiac activity signal captured using intracardiac electrodes) can be received at an amplifier (1007). Amplifier (1007) may be configured to amplify the signal (1003) for digitization by an analog-to-digital converter (ADC) (1009). The ADC (1009) can output the processed cardiac data as a stream of digitized data. The digitized data may be stored or buffered as cardiac activity data in memory (1011). The processor (1013) may analyze and/or process the buffered cardiac data in segments of predetermined size (e.g., windowed data) for ectopic cardiac activity.


In some embodiments, the analysis can be based on comparing data to one or more threshold values, e.g., predetermined and preprogrammed into the processor (1013) and/or provided by a user via a user input (1017) to a user interface (e.g., a touchscreen monitor or other type of monitor, etc.). Based on the analysis, the processor (1013) may be configured to output a cardiac activity status to a controller for generating an ablation waveform or pulse generator controller (e.g., the signal generator (122) or the controller (907)).


The signal (1015) may indicate one or more of pacing capture status (e.g., ECG signal in/out of synchrony with a pacing pulse) and ectopic cardiac activity status. For example, if pacing capture is not detected, the processor (1013) can send a corresponding status signal (1015) indicating a lack of pacing capture to a pulse generator controller. The processor (1013) and/or the pulse generator controller can then alert a user, e.g., through a user interface, that pacing capture is not present and ablation cannot be performed. The user can then take appropriate action such as, for example, halting an ablation procedure and/or reconfiguring the system. For example, the user may reposition one or more of an ablation device (e.g., ablation device (110)) and/or pacing device (e.g., pacing device (130)), and/or adjust other system parameters. If pacing capture is confirmed by the processor (1013), a different signal (1015) indicating readiness for ablation can be sent to the pulse generator controller, whereupon the pulse generator controller may be configured to initiate ablation when requested by a user. In some embodiments, systems and devices described herein may measure cardiac activity before, during, and after ablation energy delivery.


Additionally or alternatively, the processor (1013) can detect ectopic beats. For example, if pacing capture is confirmed but an ectopic beat is detected, the processor (1013) can be configured to send a signal (1015) to the pulse generator controller such that the pulse generator controller does not generate a pulse waveform for ablation. The processor (1013) and/or pulse generator controller can inform a user to the presence of ectopic beats and that ablation cannot be performed, e.g., via a user interface. The processor (1013) can also continue to monitor the sensed ECG signal for ectopic beats that may occur during ablation. If such ectopic beats are detected, the processor (1013) can send a signal (1015) to the pulse generator controller indicating that ablation should be paused or interrupted. The pulse generate controller, in response to receiving the signal (1015) can then half further ablation delivery, e.g., until the user adjusts the system and/or no ectopic beat activity is detected.


Methods

Also described here are methods for detecting ectopic cardiac activity during a tissue ablation process performed in a heart chamber using the systems and devices described above. The heart chamber may be the left atrial chamber and include its associated pulmonary veins. Generally, the methods described here include introducing and disposing a pacing device (e.g., pacing device (130), pacing device (210)) in contact with one or more heart chambers. The pacing device may measure cardiac activity and deliver a pacing signal to the heart using a cardiac stimulator or other processor (e.g., cardiac stimulator (128), controller (908), processor (1013)). The measured signals may be processed and analyzed to detect pacing capture and/or ectopic cardiac activity that may interfere with tissue ablation, e.g., by such processor and controllers as described herein. An ablation device (e.g., ablation device (110), ablation device (220)) may be introduced and disposed in contact with one or more pulmonary vein ostial or antral regions. A pulse waveform may be delivered by one or more electrodes (e.g., electrodes (112), electrodes (222, 224)) of the ablation device to ablate tissue. In some embodiments, detection of autonomously generated ectopic cardiac activity may drive prompt interruption of ablation energy delivery, thereby reducing the risk of inducing an arrhythmia (e.g., fibrillation). Furthermore, a cardiac pacing signal (e.g., delivered by a pacing device (e.g., pacing device (130), pacing device (210)) may synchronize the delivered pulse waveforms with the cardiac cycle. By synchronizing the delivery of ablation energy to a pacing stimulus (e.g., during a refractory period), the risk of inducing an arrhythmia such as fibrillation may be further reduced.


Additionally or alternatively, the pulse waveforms may include a plurality of levels of a hierarchy to reduce total energy delivery, e.g., as described in International Application Serial No. PCT/US2019/031135, filed on May 7, 2019, and titled “SYSTEMS, APPARATUSES AND METHODS FOR DELIVERY OF ABLATIVE ENERGY TO TISSUE,” the contents of which are hereby incorporated by reference in its entirety. The tissue ablation thus performed may be delivered in the absence of ectopic cardiac activity and in synchrony with paced heartbeats to reduce the risk of atrial and/or ventricular fibrillation and damage to healthy tissue. It should be appreciated that any of the ablation devices described herein (e.g., ablation device (110), ablation device (220)) may be used to ablate tissue using the methods discussed below as appropriate.


In some embodiments, the ablation devices described herein (e.g., ablation device (110), ablation device (220)) may be used for epicardial and/or endocardial ablation. Examples of suitable ablation catheters are described in International Application Serial No. PCT/US2019/014226.



FIG. 6 is an example method (400) of tissue ablation. In some embodiments, the voltage pulse waveforms described herein may be applied during a refractory period of the cardiac cycle so as to avoid disruption of the sinus rhythm of the heart. The method (400) includes introduction of a pacing device (e.g., pacing device (130, 210)) into an endocardial space, e.g., of a right ventricle, at (402). The pacing device may be advanced to be disposed in contact with the cardiac tissue, at (404). For example, sensor electrodes configured for cardiac activity measurement (e.g., ECG signals) and pacing electrodes configured for delivering pacing signals may be disposed in contact with an inner surface of the right ventricle. An ablation device (e.g., ablation device (110, 220)) may be introduced into an endocardial space, e.g., of a left atrium, at (406). The ablation device may be advanced to be disposed in contact with a pulmonary vein ostium, at (408). In some embodiments, a pacing signal may be generated by a cardiac stimulator (e.g., cardiac stimulator (128)) for cardiac stimulation of the heart, at (410). The pacing signal may then be applied to the heart, at (412), using the pacing electrodes of the pacing device. For example, the heart may be electrically paced with the pacing signal to ensure pacing capture to establish periodicity and predictability of the cardiac cycle. One or more of atrial and ventricular pacing may be applied. Examples of applied pacing signals relative to patient cardiac activity are described in more detail herein with respect to FIGS. 3A and 3B. One or more electrodes of the pacing device and/or ablation device may further measure cardiac activity (e.g., ECG signal) corresponding to electrical cardiac activity of the heart, at (414). In some embodiments, cardiac activity may be measured before, during, and/or after cardiac stimulation and tissue ablation.


An apparatus (e.g., apparatus (120, 903)) can process and/or analyze the cardiac signal sensed by the one or more electrodes. Based on analysis of the cardiac data, a status signal may be generated, at (416). The status signal may indicate a status of one or more of pacing capture and/or ectopic cardiac activity. For example, FIGS. 7, 9, and 10 provide more detailed examples of detecting ectopic cardiac activity. The status signal may be output to one or more of a signal generator (e.g., signal generator (122)) or any processor associated with an ablation device (110, 220) and/or output to a user interface, at (418). Based on the status signal, the signal generator may or may not generate a pulse waveform, at (420), e.g., based on predetermined criteria as described herein. For example, the pulse waveform may be generated in synchronization with the pacing signal (e.g., during a refractory period) when the status signal indicates one or more of a lack of ectopic cardiac activity (e.g., ectopic beat) in the cardiac data and confirmation of pacing capture (e.g., synchronization between the pacing signal and the cardiac cycle). For example, when pacing capture is observed over several heartbeats without ectopic cardiac activity, then the signal generator may generate a pulse waveform upon user (e.g., operator) activation. Conversely, the signal generator may be configured to inhibit pulse waveform generation and/or output an alert to the user when the cardiac activity status indicates one or more of ectopic cardiac activity (e.g., ectopic beat) in the cardiac data and/or an absence of pacing capture.


In some embodiments, pacing capture may be automatically confirmed by apparatuses described herein (e.g., apparatus (120, 903)) based on the received cardiac data. Additionally or alternatively, pacing capture may be confirmed by a user, e.g., after viewing an output of the pacing signal and cardiac signal data. For example, the user may confirm pacing capture using a user interface (e.g., an input/output device such as a touch screen monitor or other type of monitor) based on a cardiac activity output on a display. If the signal generator and/or processor, or the user viewing the displayed cardiac output, determines that there is one or more of ectopic cardiac activity and an absence of pacing capture, pulse waveform generation may be prohibited and the user may be prompted to adjust system parameters by, for example, repositioning the pacing device to improve tissue engagement and/or modify pacing signal parameters (e.g., pulse width, pulse amplitude, pulse frequency, etc.).


The generated pulse waveform may be delivered to tissue, at (422). In some embodiments, a voltage pulse waveform may be applied in a common refractory time period associated with atrial and ventricular pacing signals. Depending on the cardiac data that is captured and/or other parameters associated ablation delivery, the pulse waveform may be generated with a time offset with respect to the indication of the pacing signal. For example, the refractory time period may be offset from the pacing signal by predetermined time period, and the ablation device can be configured to deliver the pulses during the refractory time period that is offset from the pacing signal. In some embodiment, the voltage pulse waveform(s) may be applied over a series of heartbeats over corresponding refractory time periods (e.g., common refractory periods).


In some embodiments, the pulse waveform may be delivered to pulmonary vein ostium of a heart of a patient via one or more splines of a set of splines of an ablation device (e.g., ablation device (110, 220). In other embodiments, voltage pulse waveforms as described herein may be selectively delivered to electrode subsets such as anode-cathode subsets for ablation and isolation of the pulmonary vein. For example, a first electrode of a group of electrodes may be configured as an anode and a second electrode of the group of electrodes may be configured as a cathode. These steps may be repeated for a desired number of pulmonary vein ostial or antral regions to have been ablated (e.g., 1, 2, 3, or 4 ostia). Suitable examples of ablation devices and methods are described in International Application No. PCT/US2019/014226.



FIG. 7 is an example method (500) for detecting ectopic cardiac activity. In some embodiments, one or more steps of the method (500) may be performed by any one of the apparatuses described herein (e.g., apparatus (120, 903)), or any suitable processor associated with devices and methods described herein. The method (500) includes receiving a cardiac activity signal corresponding to electrical cardiac activity (e.g., ECG waveforms) of the heart, at (502). For example, the cardiac activity signal may include analog data received continuously from a set of electrodes (e.g., electrodes (216, 218)) of a pacing device (e.g., pacing device (210)) in contact with a chamber of a heart (e.g., the right ventricle). In some embodiments, a processor (e.g., controller (908), processor (1013)) or other processor associated with an ablation device may receive the cardiac activity signal and perform ectopic cardiac activity detection. The raw cardiac activity signal may be received and processed, at (504), to generate processed cardiac activity data. For example, signal processing may include signal conditioning (e.g., filtering), amplification, and digitization (e.g., using an analog-to-digital converter (ADC)) to generate processed cardiac activity data. For example, the cardiac activity signal may be sampled at a frequency in the range of about 1 kHz or sampling time intervals of about 1 ms and stored at a predetermined resolution (e.g., discrete time series of 16-bit signed integer data). A sampling time interval of 1 ms corresponds to a Nyquist frequency of 500 Hz. The processed cardiac activity data is stored in memory, at (506), such as a buffer. In some embodiments, the buffer clears the stored cardiac data based on a received pacing signal. For example, the buffer deletes the previously stored cardiac data upon receiving the next pacing pulse. In some embodiments, the pacing signal may include a predetermined pacing frequency.


The processed cardiac activity data may be analyzed for one or more of ectopic cardiac activity and pacing capture, at (508). For example, the processed cardiac activity data can be analyzed by extracting sliding windows of the data, and each sliding window can be evaluated for ectopic cardiac activity, e.g., using discrete Fourier transform methods. Specific implementations of such analysis are further described with reference to FIGS. 9 and 10. Optionally, in some embodiments, the processed cardiac activity data can be analyzed to confirm pacing capture, at (512).


In some embodiments, ectopic cardiac activity detection, at (510), may be performed in parallel with pacing capture detection, at (512). In other embodiments, pacing capture detection, at (512), can be performed prior to performing ectopic cardiac activity detection, at (510).


A status signal may be generated, at (514), based on the results of the detected ectopic cardiac activity and/or pacing capture. In some embodiments, the status signal may be output to one or more components of an ablation apparatus (e.g., apparatus (120)), including, for example, a signal or pulse generator (e.g., signal generator (122)) and/or another compute device. For example, a user interface (e.g., a user interface such as a display, including in an apparatus (120)) of a tissue ablation system may be configured to display an indication confirming pacing capture (e.g., “Pacing Capture Confirmed”) and display an “Ablation” icon configured to allow a user to initiate delivery of ablation energy to tissue. In some embodiments, the cardiac activity status need not be output to a user if pacing capture is confirmed and no ectopic beat is detected. Rather, an indication (e.g., an audio and/or visual alarm) can be made when either pacing capture cannot be confirmed or when an ectopic beat is detected.



FIGS. 9 and 10 are flow charts depicting example methods of detecting ectopic cardiac activity and/or confirming pacing capture. One or more steps of the methods may be performed by any one of the apparatuses described herein (120, 903), or any suitable processor associated with devices and methods described herein. As depicted in FIG. 9, a method of detecting ectopic cardiac activity includes receiving an ECG input, at (702). The ECG input can be, for example, ECG signal data received from a set of electrodes of a pacing device (e.g., electrodes (216, 218) of pacing device (210)). The ECG signal can be an analog signal. The ECG input can be processed, at (704), e.g., by conditioning (e.g., filtering) and/or amplifying the signal. The ECG signal can be converted from analog to digital, e.g., using an ADC, at (706). In some embodiments, the data can be sampled at a frequency to achieve sufficient resolution, e.g., at a frequency of about 1 kHz or sampling time intervals of about 1 ms, and stored as bit-based integer data (e.g., 16-bit signed integer data, 32-bit signed integer data, etc.). The digitized or sampled data can be stored in a memory (e.g., memory (126, 1011)), at (708). For example, the data can be buffered starting with each pacing signal such that each set of buffered data is associated with a single heart beat or cardiac cycle. The pacing signal data can be provided, e.g., by a pacing device (e.g., pacing device (130, 210)) and/or processor associated with a pacing device (e.g., processor (124, 908, 1013)), at (737). When a later set of data associated with a second pacing signal is received, the existing buffer can be cleared and this new data associated with the second pacing signal can be stored in the buffer.


At (710), the buffered data may be analyzed by extracting sliding windows of predetermined length. For example, beginning at a time interval equal to the pacing pulse width after the leading edge of the pacing pulse, the buffered data is extracted in sliding windows of a predetermined length (e.g., a window of 220 data points), which corresponds to a frequency resolution of approximately 4.54 Hz. The sliding window can start after the pacing pulse (i.e., after a time interval equal to the pulse width), and be advanced in discrete steps, e.g., with a step size equal to a preset number of sampling time intervals such as 10 sampling time intervals. The number of sliding windows extracted from the buffered data per cardiac cycle may depend on one or more parameters, such as, for example, a length between pacing pulses, window length, and/or step size, each of which can be a predetermined parameter.


A discrete Fourier Transform (e.g., Fast Fourier Transform) may be performed for each sliding window, at (712). The result of the Fourier Transform (e.g., amplitude) may be filtered (e.g., by a smoothing filter) to output a function ƒ corresponding to a local average over a set of neighboring values around each data point, at (714). Local peaks in function ƒ may be identified over a subrange of the data of each sliding window. For example, if a sliding window had a length of 220 data points, a subrange ranging from about 12 to about 100 (12th data point to 100th data point) can be used, which corresponds to a frequency band from about 54 Hz to about 454 Hz. While these specific sliding window lengths and frequency bands are provided as examples, it can be appreciated that other sliding window lengths and frequency bands can be used, e.g., depending on desired parameters, processing capability, etc. Analysis of peaks within the frequency band can be used to determine whether ectopic cardiac activity is present, at (720).


The processed ECG data within each sliding window can be used to detect ectopic cardiac activity. In an embodiment, an ectopic beat may be detected based on a comparison between a ratio of a peak value (ap) of ƒ over the predetermined interval (or subrange or frequency band) to the maximum value (amax) of ƒ up to the Nyquist frequency to a predetermined threshold t. In some embodiments, an ectopic beat may be detected in the sliding window when the ratio ap/amax is greater than t. Because ectopic beats increase the amount of certain frequencies in ECG signals, detection can be accomplished by identifying instances where a greater than normal amount of a frequency is present in the sampled cardiac data. In some embodiments, t may be between about 0.01 and about 0.25, between about 0.01 and about 0.2, between about 0.01 and about 0.15, including all sub-values and ranges in-between. In some embodiments, the user may input t into a user interface of a tissue ablation system, at (716). The threshold t can represent a sensitivity of the system, i.e., a system with a lower threshold t would have greater sensitivity than a system with higher threshold t.


When an ectopic beat is not detected in a particular sliding window (720: NO), the process continues onto the next sliding window. When an ectopic beat is detected (720: YES), then a status signal can be generated, at (724), e.g., that notifies a compute device and/or a user of the ectopic activity, as described above with reference to (514) in FIG. 7.


In some embodiments, received ECG data can be used to confirm pacing capture. For example, as depicted in FIG. 10, an example method for detecting ectopic beats and confirming pacing capture is depicted. Similar to the method depicted in FIG. 9, an ECG input can be received, at (802). At (804), the ECG input can be processed, e.g., by conditioning (e.g., filtering) and/or amplifying the signal. At (806), the ECG signal can be converted from analog to digital, e.g., using an ADC. At (808), the digitized data can be stored in a memory (e.g., memory (126)). For example, the digitized data can be buffered in the memory starting with each pacing signal such that each set of buffered data is associated with a single heart beat or cardiac cycle.


At (810), the buffered data may be analyzed by extracting sliding windows of the data, each sliding window having a predetermined length and being advanced in discrete steps through the buffered data. Detection of ectopic beats, e.g., via a discrete Fourier Transform of the data, at (812), filtering and analysis of the data, at (814), and detection of peaks in the Fourier Transform data that is greater than a preset threshold, at (820), can be similar to that described in FIG. 9. In some embodiments, such detection can be based on a user input (816).


With ECG data being available, pacing capture can also be confirmed, at (822). To confirm pacing capture, a subset of sampled data can be extracted from the ECG data at the start of the pacing signal, as indicated by (837). For example, ECG data associated with a predetermined time interval T (e.g., a pacing pulse duration) starting from onset of a pacing pulse can be extracted. For example, the time period may have a length of between about 5 ms and about 50 ms. Accordingly, the subset of sampled data can, for example, include the first ten to fifty data points, depending on the sampling frequency and time interval T A function g(t) may be defined by the subset of sampled data over the time interval T. In some embodiments, g(t) may represent an ECG signal scaled with respect to a maximum magnitude of the ECG signal over the time interval T. A set of moments (e.g., M0, M1, . . . , Mn) of this function over the time interval T may be calculated, and can be tracked over a predetermined number of successive pacing periods (e.g., 1, 2, 3, 4, 5 successive pacing periods). The set of moments of the function can include, for example, the first three moments, which can be computed in discretized form as average values, or as other suitable integral representations (e.g., using the trapezoidal rule, Simpson's rule, or other integral measures) of g(t), tg(t), and t2g(t) over the time interval T.


With the calculated moments, an average value An of the nth moment over a set of i successive periods may be given by: An=(Mn1+Mn2+Mn3+ . . . +Mni)/i. Accordingly, for the first three moments over 5 successive pacing periods, the average values will be:

A0=(M01+M02+ . . . M05)/5
A1=(M11+M12+ . . . M15)/5
A2=(M21+M22+ . . . M25)/5


A normalized difference between the average moment value An and the moment value for the ith time period (e.g., for five time periods, i=1, 2, . . . , 5) of a given moment n may be calculated. For the first three moments (n=1, 2, 3), the following set of equations provide this normalized difference:

Si=|A0−M0i|/A0
Ti=|A1−M1i|/A1
Ui=|A2−M2i|/A2

where the Si, Ti, and Ui values are set to zero when the corresponding one of A0, A1, or A2 are zero.


Confirmation of pacing capture may be detected based on the Si, Ti, and Ui values. For example, pacing capture over i predetermined time periods can be confirmed if for each non-zero value of An, its corresponding Si, Ti, or Ui value is less than a predetermined threshold or set of threshold values. For example, this threshold for the moment M0 can be in the range between 0 and 0.1. A small deviation of the moment Mni from the corresponding mean value indicates that the time-behavior of the ECG signal (viewed as a function of time) is morphologically consistent over successive pacing periods, thereby demonstrating pacing capture. In some embodiments, this threshold can be defined by a user, e.g., via input (816) provided by a user interface (e.g., of input/output device (127)). If pacing capture is confirmed (822), then this can be indicated, e.g., on a user interface by highlighting a “Pacing Capture Confirmed” indicator.


As described above with reference to FIG. 7, if no ectopic beat activity is detected, and pacing capture is confirmed, then an ablation device and processor(s) associated therewith (e.g., pulse generation controller (907) and other devices described herein) can be set to deliver pulsed electric field ablation. If ectopic beat activity is detected and/or pacing capture is not confirmed, then the ablation device and/or associated processor(s) can be deactivated and/or not set to delivery pulsed electric field ablation, for example, by activation of a suitable relay that disconnects the ablation device from the ablation generator. Specifically, if ectopic beat activity is detected, then it would be undesirable to deliver pulsed electric field ablation because it can cause fibrillation.


In some embodiments, hierarchical voltage pulse waveforms having a nested structure and a hierarchy of time intervals as described herein may be useful for irreversible electroporation, providing control and selectivity in different tissue types. FIG. 8 is a flowchart (600) of an embodiment of a tissue ablation process. The method (600) includes the introduction of a device (e.g., ablation device (110, 220)) into an endocardial space, e.g., of a left atrium, at (602). The ablation device may be advanced to be disposed in a pulmonary vein ostium, at (604). In embodiments where the device may include a first and second configuration (e.g., compact and expanded), the device may be introduced in the first configuration and transformed to a second configuration to contact tissue at or near the pulmonary vein antrum or ostium, at (606), with further descriptions of suitable ablation devices provided in International Application No. PCT/US2019/014226. The ablation device may include electrodes and may be configured in anode-cathode subsets, at (608), as discussed in detail above. For example, a subset of electrodes of the devices may be selected as anodes, while another subset of electrodes of the device may be selected as cathodes, with the voltage pulse waveform applied between the anodes and cathodes.


A pulse waveform may be generated by a signal generator (e.g., signal generator (122)) and may include a plurality of levels in a hierarchy, at (610). A variety of hierarchical waveforms may be generated with a signal generator as disclosed herein. For example, the pulse waveform may include a first level of a hierarchy of the pulse waveform including a first set of pulses. Each pulse has a pulse time duration and a first time interval separating successive pulses. A second level of the hierarchy of the pulse waveform may include a plurality of first sets of pulses as a second set of pulses. A second time interval may separate successive first sets of pulses. The second time interval may be at least three times the duration of the first time interval. A third level of the hierarchy of the pulse waveform may include a plurality of second sets of pulses as a third set of pulses. A third time interval may separate successive second sets of pulses. The third time interval may be at least thirty times the duration of the second level time interval. The pulse waveform generated by the signal generator may be delivered to tissue using the ablation device, at (612). As described herein, if ectopic beat activity is detected or pacing capture is not confirmed, then the delivery of pulse waveform activity may be interrupted, e.g., at (608) or (610). Examples of pulse waveforms that can be used with the ablation devices described herein are provided in International Application No. PCT/US2016/57664, filed on Oct. 19, 2016, titled “Systems, apparatuses and methods for delivery of ablative energy to tissue,” incorporated herein by reference in its entirety.


It is understood that while the examples herein identify separate monophasic and biphasic waveforms, it should be appreciated that combination waveforms, where some portions of the waveform hierarchy are monophasic while other portions are biphasic, may also be generated. A voltage pulse waveform having a hierarchical structure may be applied across different anode-cathode subsets (optionally with a time delay). As discussed above, one or more of the waveforms applied across the anode-cathode subsets may be applied during the refractory period of a cardiac cycle. The pulse waveform may be delivered to tissue. It should be appreciated that the steps described in certain figures may be combined and modified as appropriate.


It should be understood that the examples and illustrations in this disclosure serve exemplary purposes and departures and variations such as numbers of splines, number of electrodes, and so on can be built and deployed according to the teachings herein without departing from the scope of this invention. While specific parameters such as sampling frequency, time intervals and so on were given for exemplary purposes only in the description herein, it should be understood that other values of the various parameters can be used as convenient for the application by those skilled in the art based on the teachings presented in this disclosure.


As used herein, the terms “about” and/or “approximately” when used in conjunction with numerical values and/or ranges generally refer to those numerical values and/or ranges near to a recited numerical value and/or range. In some instances, the terms “about” and “approximately” may mean within ±10% of the recited value. For example, in some instances, “about 100 [units]” may mean within ±10% of 100 (e.g., from 90 to 110). The terms “about” and “approximately” may be used interchangeably.


Some embodiments described herein relate to a computer storage product with a non-transitory computer-readable medium (also may be referred to as a non-transitory processor-readable medium) having instructions or computer code thereon for performing various computer-implemented operations. The computer-readable medium (or processor-readable medium) is non-transitory in the sense that it does not include transitory propagating signals per se (e.g., a propagating electromagnetic wave carrying information on a transmission medium such as space or a cable). The media and computer code (also may be referred to as code or algorithm) may be those designed and constructed for the specific purpose or purposes. Examples of non-transitory computer-readable media include, but are not limited to, magnetic storage media such as hard disks, floppy disks, and magnetic tape; optical storage media such as Compact Disc/Digital Video Discs (CD/DVDs), Compact Disc-Read Only Memories (CD-ROMs), and holographic devices; magneto-optical storage media such as optical disks; carrier wave signal processing modules; and hardware devices that are specially configured to store and execute program code, such as Application-Specific Integrated Circuits (ASICs), Programmable Logic Devices (PLDs), Read-Only Memory (ROM) and Random-Access Memory (RAM) devices. Other embodiments described herein relate to a computer program product, which may include, for example, the instructions and/or computer code disclosed herein.


The systems, devices, and/or methods described herein may be performed by software (executed on hardware), hardware, or a combination thereof. Hardware modules may include, for example, a general-purpose processor (or microprocessor or microcontroller), a field programmable gate array (FPGA), and/or an application specific integrated circuit (ASIC). Software modules (executed on hardware) may be expressed in a variety of software languages (e.g., computer code), including C, C++, Java®, Ruby, Visual Basic®, and/or other object-oriented, procedural, or other programming language and development tools. Examples of computer code include, but are not limited to, micro-code or micro-instructions, machine instructions, such as produced by a compiler, code used to produce a web service, and files containing higher-level instructions that are executed by a computer using an interpreter. Additional examples of computer code include, but are not limited to, control signals, encrypted code, and compressed code.


The specific examples and descriptions herein are exemplary in nature and embodiments may be developed by those skilled in the art based on the material taught herein without departing from the scope of the present invention.

Claims
  • 1. A system, comprising: a first controller configured to generate a pulsed waveform and deliver the pulsed waveform in synchrony with a set of pacing pulses to an ablation device; anda second controller configured to: generate the set of pacing pulses and deliver the set of pacing pulses to a pacing device for cardiac stimulation of a heart;receive cardiac signal data of the heart;confirm pacing capture of the heart based on the cardiac signal data;monitor for ectopic activity of the heart by analyzing frequency components associated with the cardiac signal data; andgenerate and send a set of signals to the first controller based on the confirming and the monitoring.
  • 2. The system of claim 1, wherein the second controller is configured to monitor for ectopic activity by: extracting sliding windows of the cardiac signal data following delivery of each pacing pulse from the set of pacing pulses;performing discrete Fourier transforms of the sliding windows to obtain frequency components of the sliding windows;identifying peak frequencies over a subrange of frequencies in the frequency components of the sliding windows; anddetermining whether there is ectopic activity based on analyzing the peak frequencies.
  • 3. The system of claim 2, wherein the second controller is configured to determine whether there is ectopic activity by, for each sliding window: calculating a ratio of an amplitude of the peak frequency for that sliding window to a maximum amplitude of frequencies up to the Nyquist frequency of the frequency components of that sliding window; anddetermining whether the ratio is greater than a threshold value.
  • 4. The system of claim 1, wherein the second controller is configured to confirm pacing capture by: extracting portions of the cardiac signal data following delivery of a subset of successive pacing pulses from the set of pacing pulses;calculating, for each extracted portion, a set of moments of a function associated with that extracted portion; andconfirming pacing capture of the set of pacing pulses based at least on the set of moments calculated for each extracted portion.
  • 5. The system of claim 4, wherein each extracted portion of the cardiac signal data includes cardiac signal data within a predetermined time interval following an onset of a pacing pulse from the subset of successive pacing pulses.
  • 6. The system of claim 1, further comprising the pacing device, the pacing device including a first set of electrodes for cardiac stimulation of the heart and a second set of electrodes for capturing the cardiac signal data.
  • 7. The system of claim 1, further comprising the ablation device, the ablation device including a set of electrodes for generating a pulsed electric field to ablate cardiac tissue in response to receiving the pulsed waveform.
  • 8. The system of claim 1, wherein the set of signals includes a signal indicating pacing capture, the second controller configured to generate and send the signal indicating pacing capture in response to confirming pacing capture.
  • 9. The system of claim 8, wherein the set of signals includes a signal indicating ectopic activity, the second controller configured to generate and send the signal indicating ectopic activity in response to detecting ectopic activity based on the monitoring.
  • 10. An apparatus, comprising: a memory; anda processor operatively coupled to the memory, the processor configured to: extract portions of cardiac signal data following delivery of a set of successive pacing pulses to a heart;calculate, for each extracted portion, a set of moments of a function associated with that extracted portion;confirm pacing capture of the heart based at least on the set of moments calculated for each extracted portion; andin response to confirming pacing capture, generate and send a signal indicating pacing capture to a signal generator configured to generate pulsed waveforms for cardiac ablation such that the signal generator, in response to receiving the signal, is activated for generating the pulsed waveforms.
  • 11. The apparatus of claim 10, wherein each extracted portion of the cardiac signal data includes cardiac signal data within a predetermined time interval following an onset of a pacing pulse from the subset of successive pacing pulses.
  • 12. The apparatus of claim 11, wherein the predetermined time interval is between about 5 milliseconds and about 50 milliseconds.
  • 13. The apparatus of claim 10, wherein the processor is configured to confirm pacing capture by: calculating, for each moment from the set of moments, an average value of that moment by averaging values of the moments calculated for the extracted portions;calculating, for each moment from the set of moments, a normalized difference between the average value of that moment and the value of that moment calculated for each extracted portion; andconfirming pacing capture based on the normalized differences calculated for each moment from the set of moments.
  • 14. The apparatus of claim 10, wherein the processor is configured to confirm pacing capture by: calculating average values of each of the set of moments;calculating normalized differences between the average values of each of the set of moments and values of the moments calculated for the extracted portions; anddetermining when each normalized difference is less than a respective predetermined threshold.
  • 15. The apparatus of claim 10, wherein the processor is further configured to: analyze local peak frequencies of the cardiac signal data to detect ectopic activity of the heart; andin response to detecting ectopic activity, generate and send a signal indicating ectopic activity to the signal generator such that the signal generator, in response to receiving the signal indicating ectopic activity, is deactivated from generating the pulsed waveforms.
  • 16. The apparatus of claim 15, wherein the processor is configured to analyze the local peak frequencies of the cardiac signal data to detect ectopic activity by: extracting sliding windows of the cardiac signal data;performing discrete Fourier transforms of the extracted sliding windows and applying a filter to the resulting discrete Fourier transforms to produce filtered frequency outputs of the extracted sliding windows;identifying the local peak frequencies in the filtered frequency outputs; anddetecting ectopic activity based at least on values of the peak frequencies in the filtered frequency outputs.
  • 17. An apparatus, comprising: a memory; anda processor operatively coupled to the memory, the processor configured to: extract a sliding window of cardiac signal data of a heart;perform a transform of the sliding window to obtain frequency components of the data over a range of frequencies;identify a peak frequency over a subrange of the range of frequencies, the peak frequency having a value that is greater than that of the remaining frequencies in the subrange of frequencies;detect ectopic activity of the heart based on a comparison between a relative measure of the value of the peak frequency to a maximum value over the range of frequencies and a predetermined value; andin response to detecting ectopic activity, generate and send a signal indicating ectopic activity to a signal generator configured to generate pulsed waveforms for cardiac ablation such that the signal generator, in response to receiving the signal, interrupts generation of the pulse waveforms.
  • 18. The apparatus of claim 17, wherein the transform is a discrete Fourier transform.
  • 19. The apparatus of claim 17, wherein the processor is configured to detect ectopic activity by: calculating a ratio of the value of the peak frequency to the maximum value; anddetermining that the ratio is greater than the predetermined value.
  • 20. The apparatus of claim 19, wherein the predetermined value is between about 0.01 and about 0.25.
  • 21. The apparatus of claim 19, wherein the predetermined value is between about 0.01 and about 0.15.
  • 22. The apparatus of claim 17, wherein the processor is operatively coupled to a user interface, and the predetermined value is set by a user via the user interface.
  • 23. A method, comprising: extracting, by a processor, a sliding window of cardiac signal data of a heart;performing, by the processor, a transform of the sliding window to obtain frequency components of the data over a range of frequencies;identifying, by the processor, a peak frequency over a subrange of the range of frequencies, the peak frequency having a value that is greater than that of the remaining frequencies in the subrange of frequencies;detecting, by the processor, ectopic activity of the heart based on a comparison between a relative measure of the value of the peak frequency to a maximum value over the range of frequencies and a predetermined value; andin response to detecting ectopic activity, generating and sending, by the processor, a signal indicating ectopic activity to a signal generator configured to generate pulsed waveforms for cardiac ablation such that the signal generator, in response to receiving the signal, interrupts generation of the pulse waveforms.
  • 24. The method of claim 23, wherein the transform is a discrete Fourier transform.
  • 25. The method of claim 23, wherein the detecting the ectopic activity includes: calculating a ratio of the value of the peak frequency to the maximum value; anddetermining that the ratio is greater than the predetermined value.
  • 26. The method of claim 25, wherein the predetermined value is between about 0.01 and about 0.25.
  • 27. The method of claim 25, wherein the predetermined value is between about 0.01 and about 0.15.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 16/573,704, filed on Sep. 17, 2019, now issued as U.S. Pat. No. 10,625,080, the entire disclosure of which is incorporated herein by reference in its entirety.

US Referenced Citations (668)
Number Name Date Kind
4200104 Harris Apr 1980 A
4438766 Bowers Mar 1984 A
4470407 Hussein Sep 1984 A
4739759 Rexroth et al. Apr 1988 A
5234004 Hascoet et al. Aug 1993 A
5242441 Avitall Sep 1993 A
5257635 Langberg Nov 1993 A
5281213 Milder et al. Jan 1994 A
5304214 DeFord et al. Apr 1994 A
5306296 Wright et al. Apr 1994 A
5334193 Nardella Aug 1994 A
5341807 Nardella Aug 1994 A
5342301 Saab Aug 1994 A
5398683 Edwards et al. Mar 1995 A
5443463 Stern et al. Aug 1995 A
5454370 Avitall Oct 1995 A
5515848 Corbett, III et al. May 1996 A
5531685 Hemmer et al. Jul 1996 A
5545161 Imran Aug 1996 A
5558091 Acker et al. Sep 1996 A
5578040 Smith Nov 1996 A
5617854 Munsif Apr 1997 A
5624430 Eton et al. Apr 1997 A
5662108 Budd et al. Sep 1997 A
5667491 Pliquett et al. Sep 1997 A
5672170 Cho Sep 1997 A
5700243 Narciso, Jr. Dec 1997 A
5702438 Avitall Dec 1997 A
5706823 Wodlinger Jan 1998 A
5722400 Ockuly et al. Mar 1998 A
5722402 Swanson et al. Mar 1998 A
5749914 Janssen May 1998 A
5779699 Lipson Jul 1998 A
5788692 Campbell et al. Aug 1998 A
5810762 Hofmann Sep 1998 A
5833710 Jacobson Nov 1998 A
5836874 Swanson et al. Nov 1998 A
5836942 Netherly et al. Nov 1998 A
5836947 Fleischman et al. Nov 1998 A
5843154 Osypka Dec 1998 A
5849028 Chen Dec 1998 A
5863291 Schaer Jan 1999 A
5868736 Swanson et al. Feb 1999 A
5871523 Fleischman et al. Feb 1999 A
5876336 Swanson et al. Mar 1999 A
5885278 Fleischman et al. Mar 1999 A
5895404 Ruiz Apr 1999 A
5899917 Edwards et al. May 1999 A
5904709 Arndt et al. May 1999 A
5916158 Webster, Jr. Jun 1999 A
5916213 Haissaguerre et al. Jun 1999 A
5921924 Avitall Jul 1999 A
5928269 Alt Jul 1999 A
5928270 Ramsey, III Jul 1999 A
6002955 Willems et al. Dec 1999 A
6006131 Cooper et al. Dec 1999 A
6009351 Flachman Dec 1999 A
6014579 Pomeranz et al. Jan 2000 A
6029671 Stevens et al. Feb 2000 A
6033403 Tu et al. Mar 2000 A
6035238 Ingle et al. Mar 2000 A
6045550 Simpson et al. Apr 2000 A
6068653 LaFontaine May 2000 A
6071274 Thompson et al. Jun 2000 A
6071281 Burnside et al. Jun 2000 A
6074389 Levine et al. Jun 2000 A
6076012 Swanson et al. Jun 2000 A
6090104 Webster, Jr. Jul 2000 A
6096036 Bowe et al. Aug 2000 A
6113595 Muntermann Sep 2000 A
6119041 Pomeranz et al. Sep 2000 A
6120500 Bednarek et al. Sep 2000 A
6146381 Bowe et al. Nov 2000 A
6164283 Lesh Dec 2000 A
6167291 Barajas et al. Dec 2000 A
6171305 Sherman Jan 2001 B1
6216034 Hofmann et al. Apr 2001 B1
6219582 Hofstad et al. Apr 2001 B1
6223085 Dann et al. Apr 2001 B1
6231518 Grabek et al. May 2001 B1
6245064 Lesh et al. Jun 2001 B1
6251107 Schaer Jun 2001 B1
6251128 Knopp et al. Jun 2001 B1
6270476 Santoianni et al. Aug 2001 B1
6272384 Simon et al. Aug 2001 B1
6287306 Kroll et al. Sep 2001 B1
6314963 Vaska et al. Nov 2001 B1
6322559 Daulton et al. Nov 2001 B1
6350263 Wetzig et al. Feb 2002 B1
6370412 Armoundas et al. Apr 2002 B1
6391024 Sun et al. May 2002 B1
6447505 McGovern et al. Sep 2002 B2
6464699 Swanson Oct 2002 B1
6470211 Ideker et al. Oct 2002 B1
6502576 Lesh Jan 2003 B1
6503247 Swartz et al. Jan 2003 B2
6517534 McGovern et al. Feb 2003 B1
6527724 Fenici Mar 2003 B1
6527767 Wang et al. Mar 2003 B2
6592581 Bowe Jul 2003 B2
6595991 Tollner et al. Jul 2003 B2
6607520 Keane Aug 2003 B2
6623480 Kuo et al. Sep 2003 B1
6638278 Falwell et al. Oct 2003 B2
6666863 Wentzel et al. Dec 2003 B2
6669693 Friedman Dec 2003 B2
6702811 Stewart et al. Mar 2004 B2
6719756 Muntermann Apr 2004 B1
6723092 Brown et al. Apr 2004 B2
6728563 Rashidi Apr 2004 B2
6743225 Sanchez et al. Jun 2004 B2
6743226 Cosman et al. Jun 2004 B2
6743239 Kuehn et al. Jun 2004 B1
6764486 Natale Jul 2004 B2
6780181 Kroll et al. Aug 2004 B2
6805128 Pless Oct 2004 B1
6807447 Griffin, III Oct 2004 B2
6892091 Ben-Haim et al. May 2005 B1
6893438 Hall et al. May 2005 B2
6926714 Sra Aug 2005 B1
6955173 Lesh Oct 2005 B2
6960206 Keane Nov 2005 B2
6960207 Vanney et al. Nov 2005 B2
6972016 Hill, III et al. Dec 2005 B2
6973339 Govari Dec 2005 B2
6979331 Hintringer et al. Dec 2005 B2
6984232 Vanney et al. Jan 2006 B2
6985776 Kane et al. Jan 2006 B2
7001383 Keidar Feb 2006 B2
7041095 Wang et al. May 2006 B2
7113831 Hooven Sep 2006 B2
7171263 Darvish et al. Jan 2007 B2
7182725 Bonan et al. Feb 2007 B2
7195628 Falkenberg Mar 2007 B2
7207988 Leckrone et al. Apr 2007 B2
7207989 Pike, Jr. et al. Apr 2007 B2
7229402 Diaz et al. Jun 2007 B2
7229437 Johnson et al. Jun 2007 B2
7250049 Roop et al. Jul 2007 B2
7285116 de la Rama et al. Oct 2007 B2
7285119 Stewart et al. Oct 2007 B2
7326208 Vanney et al. Feb 2008 B2
7346379 Eng et al. Mar 2008 B2
7367974 Haemmerich et al. May 2008 B2
7374567 Heuser May 2008 B2
7387629 Vanney et al. Jun 2008 B2
7387630 Mest Jun 2008 B2
7387636 Cohn et al. Jun 2008 B2
7416552 Paul et al. Aug 2008 B2
7419477 Simpson et al. Sep 2008 B2
7419489 Vanney et al. Sep 2008 B2
7422591 Phan Sep 2008 B2
7429261 Kunis et al. Sep 2008 B2
7435248 Taimisto et al. Oct 2008 B2
7513896 Orszulak Apr 2009 B2
7527625 Knight et al. May 2009 B2
7578816 Boveja et al. Aug 2009 B2
7588567 Boveja et al. Sep 2009 B2
7623899 Worley et al. Nov 2009 B2
7678108 Chrisitian et al. Mar 2010 B2
7681579 Schwartz Mar 2010 B2
7771421 Stewart et al. Aug 2010 B2
7805182 Weese et al. Sep 2010 B2
7850642 Moll et al. Dec 2010 B2
7850685 Kunis et al. Dec 2010 B2
7857808 Oral et al. Dec 2010 B2
7857809 Drysen Dec 2010 B2
7869865 Govari et al. Jan 2011 B2
7896873 Hiller et al. Mar 2011 B2
7917211 Zacouto Mar 2011 B2
7918819 Karmarkar et al. Apr 2011 B2
7918850 Govari et al. Apr 2011 B2
7922714 Stevens-Wright Apr 2011 B2
7955827 Rubinsky et al. Jun 2011 B2
8048067 Davalos et al. Nov 2011 B2
8048072 Verin et al. Nov 2011 B2
8100895 Panos et al. Jan 2012 B2
8100900 Prinz et al. Jan 2012 B2
8108069 Stahler et al. Jan 2012 B2
8133220 Lee et al. Mar 2012 B2
8137342 Crossman Mar 2012 B2
8145289 Calabro′ et al. Mar 2012 B2
8147486 Honour et al. Apr 2012 B2
8160690 Wilfley et al. Apr 2012 B2
8175680 Panescu May 2012 B2
8182477 Orszulak et al. May 2012 B2
8206384 Falwell et al. Jun 2012 B2
8206385 Stangenes et al. Jun 2012 B2
8216221 Ibrahim et al. Jul 2012 B2
8221411 Francischelli et al. Jul 2012 B2
8226648 Paul et al. Jul 2012 B2
8228065 Wirtz et al. Jul 2012 B2
8235986 Kulesa et al. Aug 2012 B2
8235988 Davis et al. Aug 2012 B2
8251986 Chornenky et al. Aug 2012 B2
8282631 Davalos et al. Oct 2012 B2
8287532 Carroll et al. Oct 2012 B2
8414508 Thapliyal et al. Apr 2013 B2
8430875 Ibrahim et al. Apr 2013 B2
8433394 Harlev et al. Apr 2013 B2
8449535 Deno et al. May 2013 B2
8454594 Demarais et al. Jun 2013 B2
8463368 Harlev et al. Jun 2013 B2
8475450 Govari et al. Jul 2013 B2
8486063 Werneth et al. Jul 2013 B2
8500733 Watson Aug 2013 B2
8535304 Sklar et al. Sep 2013 B2
8538501 Venkatachalam et al. Sep 2013 B2
8562588 Hobbs et al. Oct 2013 B2
8568406 Harlev et al. Oct 2013 B2
8571635 McGee Oct 2013 B2
8571647 Harlev et al. Oct 2013 B2
8585695 Shih Nov 2013 B2
8588885 Hall et al. Nov 2013 B2
8597288 Christian Dec 2013 B2
8608735 Govari et al. Dec 2013 B2
8628522 Ibrahim et al. Jan 2014 B2
8632534 Pearson et al. Jan 2014 B2
8647338 Chornenky et al. Feb 2014 B2
8708952 Cohen et al. Apr 2014 B2
8734442 Cao et al. May 2014 B2
8771267 Kunis et al. Jul 2014 B2
8795310 Fung et al. Aug 2014 B2
8808273 Caples et al. Aug 2014 B2
8808281 Emons et al. Aug 2014 B2
8834461 Werneth et al. Sep 2014 B2
8834464 Stewart et al. Sep 2014 B2
8868169 Narayan et al. Oct 2014 B2
8876817 Avitall et al. Nov 2014 B2
8880195 Azure Nov 2014 B2
8886309 Luther et al. Nov 2014 B2
8903488 Callas et al. Dec 2014 B2
8920411 Gelbart et al. Dec 2014 B2
8926589 Govari Jan 2015 B2
8932287 Gelbart et al. Jan 2015 B2
8945117 Bencini Feb 2015 B2
8979841 Kunis et al. Mar 2015 B2
8986278 Fung et al. Mar 2015 B2
9002442 Harley et al. Apr 2015 B2
9005189 Davalos et al. Apr 2015 B2
9005194 Oral et al. Apr 2015 B2
9011425 Fischer et al. Apr 2015 B2
9044245 Condie et al. Jun 2015 B2
9055959 Vaska et al. Jun 2015 B2
9072518 Swanson Jul 2015 B2
9078667 Besser et al. Jul 2015 B2
9101374 Hoch et al. Aug 2015 B1
9119533 Ghaffari Sep 2015 B2
9119634 Gelbart et al. Sep 2015 B2
9131897 Harada et al. Sep 2015 B2
9155590 Mathur Oct 2015 B2
9162037 Belson et al. Oct 2015 B2
9179972 Olson Nov 2015 B2
9186481 Avitall et al. Nov 2015 B2
9192769 Donofrio et al. Nov 2015 B2
9211405 Mahapatra et al. Dec 2015 B2
9216055 Spence et al. Dec 2015 B2
9233248 Luther et al. Jan 2016 B2
9237926 Nollert et al. Jan 2016 B2
9262252 Kirkpatrick et al. Feb 2016 B2
9277957 Long et al. Mar 2016 B2
9282910 Narayan et al. Mar 2016 B2
9289258 Cohen Mar 2016 B2
9289606 Paul et al. Mar 2016 B2
9295516 Pearson et al. Mar 2016 B2
9301801 Scheib Apr 2016 B2
9375268 Long Jun 2016 B2
9414881 Callas et al. Aug 2016 B2
9468495 Kunis et al. Oct 2016 B2
9474486 Eliason et al. Oct 2016 B2
9474574 Ibrahim et al. Oct 2016 B2
9480525 Lopes et al. Nov 2016 B2
9486272 Bonyak et al. Nov 2016 B2
9486273 Lopes et al. Nov 2016 B2
9492227 Lopes et al. Nov 2016 B2
9492228 Lopes et al. Nov 2016 B2
9517103 Panescu et al. Dec 2016 B2
9526573 Lopes et al. Dec 2016 B2
9532831 Reinders et al. Jan 2017 B2
9539010 Gagner et al. Jan 2017 B2
9554848 Stewart et al. Jan 2017 B2
9554851 Sklar et al. Jan 2017 B2
9700368 Callas et al. Jul 2017 B2
9724170 Mickelsen Aug 2017 B2
9757193 Zarins et al. Sep 2017 B2
9782099 Williams et al. Oct 2017 B2
9788885 Long et al. Oct 2017 B2
9795442 Salahieh et al. Oct 2017 B2
9861802 Mickelsen Jan 2018 B2
9913685 Clark et al. Mar 2018 B2
9931487 Quinn et al. Apr 2018 B2
9987081 Bowers et al. Jun 2018 B1
9999465 Long et al. Jun 2018 B2
10016232 Bowers et al. Jul 2018 B1
10117701 Davalos et al. Nov 2018 B2
10117707 Garcia et al. Nov 2018 B2
10130423 Viswanathan et al. Nov 2018 B1
10172673 Viswanathan et al. Jan 2019 B2
10292755 Arena et al. May 2019 B2
10322286 Viswanathan et al. Jun 2019 B2
10342598 Long et al. Jul 2019 B2
10433906 Mickelsen Oct 2019 B2
10433908 Viswanathan et al. Oct 2019 B2
10448989 Arena et al. Oct 2019 B2
10507302 Leeflang et al. Dec 2019 B2
10512505 Viswanathan Dec 2019 B2
10512779 Viswanathan et al. Dec 2019 B2
10517672 Long Dec 2019 B2
10531914 Stewart et al. Jan 2020 B2
20010000791 Suorsa et al. May 2001 A1
20010007070 Stewart et al. Jul 2001 A1
20010044624 Seraj et al. Nov 2001 A1
20020052602 Wang et al. May 2002 A1
20020077627 Johnson et al. Jun 2002 A1
20020087169 Brock et al. Jul 2002 A1
20020091384 Hooven et al. Jul 2002 A1
20020095176 Liddicoat et al. Jul 2002 A1
20020111618 Stewart et al. Aug 2002 A1
20020156526 Hlavka et al. Oct 2002 A1
20020161323 Miller et al. Oct 2002 A1
20020169445 Jain et al. Nov 2002 A1
20020177765 Bowe et al. Nov 2002 A1
20020183638 Swanson Dec 2002 A1
20030014098 Quijano et al. Jan 2003 A1
20030018374 Paulos Jan 2003 A1
20030023287 Edwards et al. Jan 2003 A1
20030028189 Woloszko et al. Feb 2003 A1
20030050637 Maguire et al. Mar 2003 A1
20030114849 Ryan Jun 2003 A1
20030125729 Hooven et al. Jul 2003 A1
20030130598 Manning et al. Jul 2003 A1
20030130711 Pearson et al. Jul 2003 A1
20030204161 Ferek Petric Oct 2003 A1
20030229379 Ramsey Dec 2003 A1
20040039382 Kroll et al. Feb 2004 A1
20040049181 Stewart et al. Mar 2004 A1
20040049182 Koblish et al. Mar 2004 A1
20040082859 Schaer Apr 2004 A1
20040082948 Stewart et al. Apr 2004 A1
20040087939 Eggers et al. May 2004 A1
20040111087 Stern et al. Jun 2004 A1
20040199157 Palanker et al. Oct 2004 A1
20040215139 Cohen Oct 2004 A1
20040231683 Eng et al. Nov 2004 A1
20040236360 Cohn et al. Nov 2004 A1
20040254607 Wittenberger et al. Dec 2004 A1
20040267337 Hayzelden Dec 2004 A1
20050033282 Hooven Feb 2005 A1
20050187545 Hooven et al. Aug 2005 A1
20050222632 Obino Oct 2005 A1
20050251130 Boveja et al. Nov 2005 A1
20050261672 Deem et al. Nov 2005 A1
20060009755 Sra Jan 2006 A1
20060009759 Chrisitian et al. Jan 2006 A1
20060015095 Desinger et al. Jan 2006 A1
20060015165 Bertolero et al. Jan 2006 A1
20060024359 Walker et al. Feb 2006 A1
20060058781 Long Mar 2006 A1
20060111702 Oral et al. May 2006 A1
20060142801 Demarais et al. Jun 2006 A1
20060167448 Kozel Jul 2006 A1
20060217703 Chornenky et al. Sep 2006 A1
20060241734 Marshall et al. Oct 2006 A1
20060264752 Rubinsky et al. Nov 2006 A1
20060270900 Chin et al. Nov 2006 A1
20060287648 Schwartz Dec 2006 A1
20060293730 Rubinsky et al. Dec 2006 A1
20060293731 Rubinsky et al. Dec 2006 A1
20070005053 Dando Jan 2007 A1
20070021744 Creighton Jan 2007 A1
20070060989 Deem et al. Mar 2007 A1
20070066972 Ormsby et al. Mar 2007 A1
20070129721 Phan et al. Jun 2007 A1
20070129760 Demarais et al. Jun 2007 A1
20070156135 Rubinsky et al. Jul 2007 A1
20070167740 Grunewald et al. Jul 2007 A1
20070167940 Stevens-Wright Jul 2007 A1
20070173878 Heuser Jul 2007 A1
20070208329 Ward et al. Sep 2007 A1
20070225589 Viswanathan Sep 2007 A1
20070249923 Keenan Oct 2007 A1
20070260223 Scheibe et al. Nov 2007 A1
20070270792 Hennemann et al. Nov 2007 A1
20080009855 Hamou Jan 2008 A1
20080033426 Machell Feb 2008 A1
20080065061 Viswanathan Mar 2008 A1
20080086120 Mirza et al. Apr 2008 A1
20080091195 Silwa et al. Apr 2008 A1
20080103545 Bolea et al. May 2008 A1
20080132885 Rubinsky et al. Jun 2008 A1
20080161789 Thao et al. Jul 2008 A1
20080172048 Martin et al. Jul 2008 A1
20080200913 Viswanathan Aug 2008 A1
20080208118 Goldman Aug 2008 A1
20080243214 Koblish Oct 2008 A1
20080281322 Sherman et al. Nov 2008 A1
20080300574 Belson et al. Dec 2008 A1
20080300588 Groth et al. Dec 2008 A1
20090024084 Khosla et al. Jan 2009 A1
20090048591 Ibrahim et al. Feb 2009 A1
20090062788 Long et al. Mar 2009 A1
20090076500 Azure Mar 2009 A1
20090105654 Kurth et al. Apr 2009 A1
20090138009 Viswanathan et al. May 2009 A1
20090149917 Whitehurst et al. Jun 2009 A1
20090163905 Winkler et al. Jun 2009 A1
20090228003 Sinelnikov Sep 2009 A1
20090240248 Deford et al. Sep 2009 A1
20090275827 Aiken et al. Nov 2009 A1
20090281477 Mikus et al. Nov 2009 A1
20090306651 Schneider Dec 2009 A1
20100004623 Hamilton et al. Jan 2010 A1
20100023004 Francischelli et al. Jan 2010 A1
20100137861 Soroff et al. Jun 2010 A1
20100185140 Kassab et al. Jul 2010 A1
20100185186 Longoria Jul 2010 A1
20100191112 Demarais et al. Jul 2010 A1
20100191232 Boveda Jul 2010 A1
20100241185 Mahapatra et al. Sep 2010 A1
20100261994 Davalos et al. Oct 2010 A1
20100274238 Klimovitch Oct 2010 A1
20100280513 Juergen et al. Nov 2010 A1
20100280539 Miyoshi et al. Nov 2010 A1
20100292687 Kauphusman et al. Nov 2010 A1
20100312096 Guttman et al. Dec 2010 A1
20100312300 Ryu et al. Dec 2010 A1
20110028962 Werneth et al. Feb 2011 A1
20110028964 Edwards Feb 2011 A1
20110040199 Hopenfeld Feb 2011 A1
20110098694 Long Apr 2011 A1
20110106221 Neal, II et al. May 2011 A1
20110130708 Perry et al. Jun 2011 A1
20110144524 Fish et al. Jun 2011 A1
20110144633 Govari Jun 2011 A1
20110160785 Mon et al. Jun 2011 A1
20110190659 Long et al. Aug 2011 A1
20110190727 Edmunds et al. Aug 2011 A1
20110213231 Hall et al. Sep 2011 A1
20110276047 Sklar et al. Nov 2011 A1
20110276075 Fung et al. Nov 2011 A1
20110288544 Verin et al. Nov 2011 A1
20110288547 Morgan et al. Nov 2011 A1
20110313417 De La Rama et al. Dec 2011 A1
20120029512 Willard et al. Feb 2012 A1
20120046570 Villegas et al. Feb 2012 A1
20120053581 Wittkampf et al. Mar 2012 A1
20120059255 Paul et al. Mar 2012 A1
20120071872 Rubinsky et al. Mar 2012 A1
20120078320 Schotzko et al. Mar 2012 A1
20120078343 Fish Mar 2012 A1
20120089089 Swain et al. Apr 2012 A1
20120095459 Callas et al. Apr 2012 A1
20120101413 Beetel et al. Apr 2012 A1
20120158021 Morrill Jun 2012 A1
20120165667 Altmann et al. Jun 2012 A1
20120172859 Condie et al. Jul 2012 A1
20120172867 Ryu et al. Jul 2012 A1
20120197100 Razavi et al. Aug 2012 A1
20120209260 Lambert et al. Aug 2012 A1
20120220998 Long et al. Aug 2012 A1
20120265198 Crow et al. Oct 2012 A1
20120283582 Mahapatra et al. Nov 2012 A1
20120303019 Zhao et al. Nov 2012 A1
20120310052 Mahapatra et al. Dec 2012 A1
20120310230 Willis Dec 2012 A1
20120310237 Swanson Dec 2012 A1
20120316557 Sartor et al. Dec 2012 A1
20130030430 Stewart et al. Jan 2013 A1
20130060247 Sklar et al. Mar 2013 A1
20130060248 Sklar et al. Mar 2013 A1
20130079768 De Luca et al. Mar 2013 A1
20130090651 Smith Apr 2013 A1
20130096655 Moffitt et al. Apr 2013 A1
20130103027 Sklar et al. Apr 2013 A1
20130103064 Arenson et al. Apr 2013 A1
20130131662 Wittkampf May 2013 A1
20130158538 Govari Jun 2013 A1
20130158621 Ding et al. Jun 2013 A1
20130172715 Just et al. Jul 2013 A1
20130172864 Ibrahim et al. Jul 2013 A1
20130172875 Govari et al. Jul 2013 A1
20130184702 Neal, II et al. Jul 2013 A1
20130218157 Callas et al. Aug 2013 A1
20130226174 Ibrahim et al. Aug 2013 A1
20130237984 Sklar Sep 2013 A1
20130253415 Sano et al. Sep 2013 A1
20130296679 Condie et al. Nov 2013 A1
20130310829 Cohen Nov 2013 A1
20130317385 Sklar et al. Nov 2013 A1
20130331831 Werneth et al. Dec 2013 A1
20130338467 Grasse et al. Dec 2013 A1
20140005664 Govari et al. Jan 2014 A1
20140024911 Harlev et al. Jan 2014 A1
20140039288 Shih Feb 2014 A1
20140051993 McGee Feb 2014 A1
20140052118 Laske et al. Feb 2014 A1
20140052126 Long et al. Feb 2014 A1
20140052216 Long et al. Feb 2014 A1
20140058377 Deem et al. Feb 2014 A1
20140081113 Cohen et al. Mar 2014 A1
20140100563 Govari et al. Apr 2014 A1
20140107644 Falwell et al. Apr 2014 A1
20140142408 De La Rama et al. May 2014 A1
20140148804 Ward et al. May 2014 A1
20140163480 Govari et al. Jun 2014 A1
20140163546 Govari et al. Jun 2014 A1
20140171942 Werneth et al. Jun 2014 A1
20140180035 Anderson Jun 2014 A1
20140187916 Clark et al. Jul 2014 A1
20140194716 Diep et al. Jul 2014 A1
20140194867 Fish et al. Jul 2014 A1
20140200567 Cox et al. Jul 2014 A1
20140235986 Harlev et al. Aug 2014 A1
20140235988 Ghosh Aug 2014 A1
20140235989 Wodlinger et al. Aug 2014 A1
20140243851 Cohen et al. Aug 2014 A1
20140276760 Bonyak et al. Sep 2014 A1
20140276782 Paskar Sep 2014 A1
20140276791 Ku et al. Sep 2014 A1
20140288556 Ibrahim et al. Sep 2014 A1
20140303721 Fung et al. Oct 2014 A1
20140343549 Spear et al. Nov 2014 A1
20140364845 Rashidi Dec 2014 A1
20140371613 Narayan et al. Dec 2014 A1
20150005767 Werneth et al. Jan 2015 A1
20150011995 Avitall et al. Jan 2015 A1
20150066108 Shi et al. Mar 2015 A1
20150119674 Fischell et al. Apr 2015 A1
20150126840 Thakur et al. May 2015 A1
20150133914 Koblish May 2015 A1
20150138977 Dacosta May 2015 A1
20150141978 Subramaniam et al. May 2015 A1
20150142041 Kendale et al. May 2015 A1
20150148796 Bencini May 2015 A1
20150150472 Harlev et al. Jun 2015 A1
20150157402 Kunis et al. Jun 2015 A1
20150157412 Wallace et al. Jun 2015 A1
20150164584 Davalos et al. Jun 2015 A1
20150173824 Davalos et al. Jun 2015 A1
20150173828 Avitall Jun 2015 A1
20150174404 Rousso et al. Jun 2015 A1
20150182740 Mickelsen Jul 2015 A1
20150196217 Harlev et al. Jul 2015 A1
20150223726 Harlev et al. Aug 2015 A1
20150230699 Berul et al. Aug 2015 A1
20150258344 Tandri et al. Sep 2015 A1
20150265342 Long et al. Sep 2015 A1
20150265344 Aktas et al. Sep 2015 A1
20150272656 Chen Oct 2015 A1
20150272664 Cohen Oct 2015 A9
20150272667 Govari et al. Oct 2015 A1
20150282729 Harlev et al. Oct 2015 A1
20150289923 Davalos et al. Oct 2015 A1
20150304879 Dacosta Oct 2015 A1
20150320481 Cosman et al. Nov 2015 A1
20150321021 Tandri et al. Nov 2015 A1
20150327944 Neal, II et al. Nov 2015 A1
20150342532 Basu et al. Dec 2015 A1
20150343212 Rousso et al. Dec 2015 A1
20150351836 Prutchi Dec 2015 A1
20150359583 Swanson Dec 2015 A1
20160000500 Salahieh et al. Jan 2016 A1
20160008061 Fung et al. Jan 2016 A1
20160008065 Gliner et al. Jan 2016 A1
20160029960 Toth et al. Feb 2016 A1
20160038772 Thapliyal et al. Feb 2016 A1
20160051204 Harlev et al. Feb 2016 A1
20160051324 Stewart et al. Feb 2016 A1
20160058493 Neal, II et al. Mar 2016 A1
20160058506 Spence et al. Mar 2016 A1
20160066993 Avitall et al. Mar 2016 A1
20160074679 Thapliyal et al. Mar 2016 A1
20160095531 Narayan et al. Apr 2016 A1
20160095642 Deno et al. Apr 2016 A1
20160095653 Lambert et al. Apr 2016 A1
20160100797 Mahapatra et al. Apr 2016 A1
20160100884 Fay et al. Apr 2016 A1
20160106498 Highsmith et al. Apr 2016 A1
20160106500 Olson Apr 2016 A1
20160113709 Maor Apr 2016 A1
20160113712 Cheung et al. Apr 2016 A1
20160120564 Kirkpatrick et al. May 2016 A1
20160128770 Afonso et al. May 2016 A1
20160166167 Narayan et al. Jun 2016 A1
20160166310 Stewart et al. Jun 2016 A1
20160166311 Long et al. Jun 2016 A1
20160174865 Stewart et al. Jun 2016 A1
20160183877 Williams et al. Jun 2016 A1
20160184003 Srimathveeravalli et al. Jun 2016 A1
20160184004 Hull et al. Jun 2016 A1
20160213282 Leo et al. Jul 2016 A1
20160220307 Miller et al. Aug 2016 A1
20160235470 Callas et al. Aug 2016 A1
20160287314 Arena et al. Oct 2016 A1
20160310211 Long Oct 2016 A1
20160324564 Gerlach et al. Nov 2016 A1
20160324573 Mickelsen et al. Nov 2016 A1
20160331441 Konings Nov 2016 A1
20160331459 Townley et al. Nov 2016 A1
20160354142 Pearson et al. Dec 2016 A1
20160361109 Weaver et al. Dec 2016 A1
20170001016 De Ridder Jan 2017 A1
20170035499 Stewart et al. Feb 2017 A1
20170042449 Deno et al. Feb 2017 A1
20170042615 Salahieh et al. Feb 2017 A1
20170056648 Syed et al. Mar 2017 A1
20170065330 Mickelsen et al. Mar 2017 A1
20170065339 Mickelsen Mar 2017 A1
20170065340 Long Mar 2017 A1
20170065343 Mickelsen Mar 2017 A1
20170071543 Basu et al. Mar 2017 A1
20170095291 Harrington et al. Apr 2017 A1
20170105793 Cao et al. Apr 2017 A1
20170146584 Daw et al. May 2017 A1
20170151029 Mickelsen Jun 2017 A1
20170172654 Wittkampf et al. Jun 2017 A1
20170181795 Debruyne Jun 2017 A1
20170189097 Viswanathan et al. Jul 2017 A1
20170215953 Long et al. Aug 2017 A1
20170245928 Xiao et al. Aug 2017 A1
20170246455 Athos et al. Aug 2017 A1
20170312024 Harlev et al. Nov 2017 A1
20170312025 Harlev et al. Nov 2017 A1
20170312027 Harlev et al. Nov 2017 A1
20180001056 Leeflang et al. Jan 2018 A1
20180042674 Mickelsen Feb 2018 A1
20180042675 Long Feb 2018 A1
20180043153 Viswanathan et al. Feb 2018 A1
20180064488 Long et al. Mar 2018 A1
20180085160 Viswanathan et al. Mar 2018 A1
20180093088 Mickelsen Apr 2018 A1
20180133460 Townley et al. May 2018 A1
20180168511 Hall et al. Jun 2018 A1
20180184982 Basu et al. Jul 2018 A1
20180193090 de la Rama et al. Jul 2018 A1
20180200497 Mickelsen Jul 2018 A1
20180214195 Fraasch et al. Aug 2018 A1
20180214202 Howard et al. Aug 2018 A1
20180221078 Howard et al. Aug 2018 A1
20180243558 Athos et al. Aug 2018 A1
20180250508 Howard Sep 2018 A1
20180289417 Schweitzer et al. Oct 2018 A1
20180303488 Hill Oct 2018 A1
20180303543 Stewart et al. Oct 2018 A1
20180311497 Viswanathan et al. Nov 2018 A1
20180344393 Gruba et al. Dec 2018 A1
20180360534 Teplitsky et al. Dec 2018 A1
20190038171 Howard Feb 2019 A1
20190060632 Asirvatham et al. Feb 2019 A1
20190069950 Viswanathan et al. Mar 2019 A1
20190125439 Rohl et al. May 2019 A1
20190151015 Viswanathan et al. May 2019 A1
20190183378 Mosesov et al. Jun 2019 A1
20190192223 Rankin Jun 2019 A1
20190201089 Waldstreicher et al. Jul 2019 A1
20190209238 Jimenez Jul 2019 A1
20190223938 Arena et al. Jul 2019 A1
20190223950 Gelbart et al. Jul 2019 A1
20190231421 Viswanathan et al. Aug 2019 A1
20190231425 Waldstreicher et al. Aug 2019 A1
20190233809 Neal, II et al. Aug 2019 A1
20190256839 Neal, II et al. Aug 2019 A1
20190269912 Viswanathan et al. Sep 2019 A1
20190328445 Sano et al. Oct 2019 A1
20190336198 Viswanathan et al. Nov 2019 A1
20190336207 Viswanathan Nov 2019 A1
20190350647 Ramberg et al. Nov 2019 A1
20190376055 Davalos et al. Dec 2019 A1
Foreign Referenced Citations (96)
Number Date Country
1042990 Oct 2000 EP
1125549 Aug 2001 EP
0797956 Jun 2003 EP
1127552 Jun 2006 EP
1340469 Mar 2007 EP
1009303 Jun 2009 EP
2213729 Aug 2010 EP
2425871 Mar 2012 EP
1803411 Aug 2012 EP
2532320 Dec 2012 EP
2587275 May 2013 EP
2663227 Nov 2013 EP
1909678 Jan 2014 EP
2217165 Mar 2014 EP
2376193 Mar 2014 EP
2708181 Mar 2014 EP
2777579 Sep 2014 EP
2934307 Oct 2015 EP
2777585 Jun 2016 EP
2382935 Mar 2018 EP
3111871 Mar 2018 EP
3151773 Apr 2018 EP
3056242 Jul 2018 EP
H06-507797 Sep 1994 JP
H10-510745 Oct 1998 JP
2000-508196 Jul 2000 JP
2005-516666 Jun 2005 JP
2006-506184 Feb 2006 JP
2007-325935 Dec 2007 JP
2008-538997 Nov 2008 JP
2009-500129 Jan 2009 JP
2011-509158 Mar 2011 JP
2012-050538 Mar 2012 JP
WO 9207622 May 1992 WO
WO 9221278 Dec 1992 WO
WO 9221285 Dec 1992 WO
WO 9407413 Apr 1994 WO
WO 9724073 Jul 1997 WO
WO 9725917 Jul 1997 WO
WO 9737719 Oct 1997 WO
WO 1999004851 Feb 1999 WO
WO 1999022659 May 1999 WO
WO 1999056650 Nov 1999 WO
WO 1999059486 Nov 1999 WO
WO 2002056782 Jul 2002 WO
WO 2003053289 Jul 2003 WO
WO 2003065916 Aug 2003 WO
WO 2004045442 Jun 2004 WO
WO 2004086994 Oct 2004 WO
WO 2005046487 May 2005 WO
WO 2006115902 Nov 2006 WO
WO 2007006055 Jan 2007 WO
WO 2007079438 Jul 2007 WO
WO 2009082710 Jul 2009 WO
WO 2009089343 Jul 2009 WO
WO 2009137800 Nov 2009 WO
WO 2010014480 Feb 2010 WO
WO 2011028310 Mar 2011 WO
WO 2011154805 Dec 2011 WO
WO 2012051433 Apr 2012 WO
WO 2012153928 Nov 2012 WO
WO 2013019385 Feb 2013 WO
WO 2014025394 Feb 2014 WO
WO 2014031800 Feb 2014 WO
WO 2014036439 Mar 2014 WO
WO 2014160832 Oct 2014 WO
WO 2015066322 May 2015 WO
WO 2015099786 Jul 2015 WO
WO 2015103530 Jul 2015 WO
WO 2015103574 Jul 2015 WO
WO 2015130824 Sep 2015 WO
WO 2015140741 Sep 2015 WO
WO 2015143327 Sep 2015 WO
WO 2015171921 Nov 2015 WO
WO 2015175944 Nov 2015 WO
WO 2015192018 Dec 2015 WO
WO 2015192027 Dec 2015 WO
WO 2016059027 Apr 2016 WO
WO 2016060983 Apr 2016 WO
WO 2016081650 May 2016 WO
WO 2016090175 Jun 2016 WO
WO 2017093926 Jun 2017 WO
WO 2017119934 Jul 2017 WO
WO 2017120169 Jul 2017 WO
WO 2017192477 Nov 2017 WO
WO 2017192495 Nov 2017 WO
WO 2017218734 Dec 2017 WO
WO 2018005511 Jan 2018 WO
WO 2018200800 Nov 2018 WO
WO 2018208795 Nov 2018 WO
WO 2019118436 Jun 2019 WO
WO 2019133606 Jul 2019 WO
WO 2019133608 Jul 2019 WO
WO 2019147832 Aug 2019 WO
WO 2019152986 Aug 2019 WO
WO 2019173309 Sep 2019 WO
Non-Patent Literature Citations (103)
Entry
Partial Supplementary European Search Report for European Application No. 13827672.0, dated Mar. 23, 2016, 6 pages.
Supplementary European Search Report for European Application No. 13827672.0, dated Jul. 11, 2016, 12 pages.
Office Action for European Application No. 13827672.0, dated Feb. 5, 2018, 6 pages.
Notice of Reasons for Rejection for Japanese Application No. 2015-526522, dated Mar. 6, 2017, 3 pages.
Office Action for U.S. Appl. No. 14/400,455, dated Mar. 30, 2017, 10 pages.
International Search Report and Written Opinion for International Application No. PCT/US2013/031252, dated Jul. 19, 2013, 12 pages.
Office Action for U.S. Appl. No. 15/819,726, dated Jun. 4, 2018, 17 pages.
Office Action for U.S. Appl. No. 15/917,194, dated Jun. 4, 2018, 17 pages.
Office Action for U.S. Appl. No. 15/917,194, dated Oct. 9, 2018, 13 pages.
First Office Action for Chinese Application No. 201580006848.8, dated Jan. 29, 2018, 15 pages.
Office Action for U.S. Appl. No. 15/201,997, dated Dec. 17, 2018, 17 pages.
International Search Report and Written Opinion for International Application No. PCT/US2018/050660, dated Nov. 26, 2018, 13 pages.
Office Action for European Application No. 15701856.5, dated Dec. 11, 2017, 6 pages.
Notice of Reasons for Rejection for Japanese Application No. 2016-544072, dated Oct. 1, 2018, 11 pages.
International Search Report and Written Opinion for International Application No. PCT/US2015/010138, dated Mar. 26, 2015, 14 pages.
International Preliminary Report on Patentability for International Application No. PCT/US2015/010138, dated Jul. 12, 2016, 9 pages.
Supplementary European Search Report for European Application No. 15733297.4, dated Aug. 10, 2017, 7 pages.
Office Action for U.S. Appl. No. 15/201,997, dated Apr. 3, 2017, 6 pages.
Office Action for U.S. Appl. No. 15/201,997, dated Aug. 29, 2017, 12 pages.
Office Action for U.S. Appl. No. 15/201,997, dated Jul. 12, 2018, 12 pages.
International Search Report and Written Opinion for International Application No. PCT/US2015/010223, dated Apr. 10, 2015, 19 pages.
International Preliminary Report on Patentability for International Application No. PCT/US2015/010223, dated Jul. 12, 2016, 12 pages.
International Search Report and Written Opinion for International Application No. PCT/US2015/029734, dated Nov. 24, 2015, 15 pages.
Office Action for U.S. Appl. No. 15/795,062, dated Dec. 19, 2017, 14 pages.
Office Action for U.S. Appl. No. 15/795,062, dated Apr. 9, 2018, 20 pages.
International Search Report and Written Opinion for International Application No. PCT/US2015/031086, dated Oct. 21, 2015, 16 pages.
Office Action for U.S. Appl. No. 15/795,075, dated Feb. 6, 2018, 9 pages.
Office Action for U.S. Appl. No. 15/795,075, dated Jun. 15, 2018, 10 pages.
Extended European Search Report for European Application No. 15849844.4, dated May 3, 2018, 8 pages.
International Search Report and Written Opinion for International Application No. PCT/US2015/055105, dated Mar. 1, 2016, 15 pages.
Office Action for U.S. Appl. No. 15/796,255, dated Jan. 10, 2018, 12 pages.
Extended European Search Report for European Application No. 15806855.1, dated Jan. 3, 2018, 8 pages.
International Search Report and Written Opinion for International Application No. PCT/US2015/035582, dated Oct. 2, 2015, 17 pages.
Extended European Search Report for European Application No. 15806278.6, dated Feb. 9, 2018, 5 pages.
International Search Report and Written Opinion for International Application No. PCT/US2015/035592, dated Oct. 2, 2015, 13 pages.
Office Action for U.S. Appl. No. 15/334,646, dated Jul. 25, 2017, 19 pages.
Office Action for U.S. Appl. No. 15/334,646, dated Nov. 16, 2017, 26 pages.
International Search Report and Written Opinion for International Application No. PCT/US2016/057664, dated Feb. 24, 2017, 11 pages.
Office Action for U.S. Appl. No. 15/796,375, dated Jan. 24, 2018, 25 pages.
Office Action for U.S. Appl. No. 15/796,375, dated May 30, 2018, 26 pages.
Office Action for U.S. Appl. No. 15/796,375, dated Nov. 16, 2018, 27 pages.
International Search Report and Written Opinion for International Application No. PCT/US2017/012099, dated May 18, 2017, 17 pages.
Office Action for U.S. Appl. No. 15/711,266, dated Feb. 23, 2018, 14 pages.
International Search Report and Written Opinion for International Application No. PCT/US2018/029938, dated Aug. 29, 2018, 14 pages.
International Search Report and Written Opinion for International Application No. PCT/US2017/037609, dated Nov. 8, 2017, 13 pages.
Office Action for U.S. Appl. No. 15/672,916, dated Feb. 13, 2018, 16 pages.
Office Action for U.S. Appl. No. 15/672,916, dated Jul. 20, 2018, 23 pages.
Office Action for U.S. Appl. No. 15/499,804, dated Jan. 3, 2018, 20 pages.
Office Action for U.S. Appl. No. 15/794,717, dated Feb. 1, 2018, 10 pages.
International Search Report and Written Opinion for International Application No. PCT/US2018/029552, dated Jun. 29, 2018, 13 pages.
Office Action for U.S. Appl. No. 15/970,404, dated Oct. 9, 2018, 21 pages.
du Pre, B.C. et al., “Minimal coronary artery damage by myocardial electroporation ablation,” Europace, 15(1):144-149 (2013).
Hobbs, E. P., “Investor Relations Update: Tissue Ablation via Irreversible Electroporation (IRE),” Powerpoint (2004), 16 pages.
Lavee, J. et al., “A Novel Nonthermal Energy Source for Surgical Epicardial Atrial Ablation: Irreversible Electroporation,” The Heart Surgery Forum #2006-1202, 10(2), 2007 [Epub Mar. 2007].
Madhavan, M. et al., “Novel Percutaneous Epicardial Autonomic Modulation in the Canine for Atrial Fibrillation: Results of an Efficacy and Safety Study,” Pace, 00:1-11 (2016).
Neven, K. et al., “Safety and Feasibility of Closed Chest Epicardial Catheter Ablation Using Electroporation,” Circ Arrhythm Electrophysiol., 7:913-919 (2014).
Neven, K. et al., “Myocardial Lesion Size After Epicardial Electroporation Catheter Ablation After Subxiphoid Puncture,” Circ Arrhythm Electrophysiol., 7(4):728-733 (2014).
Neven, K. et al., “Epicardial linear electroporation ablation and lesion size,” Heart Rhythm, 11:1465-1470 (2014).
van Driel, V.J.H.M. et al., “Pulmonary Vein Stenosis After Catheter Ablation Electroporation Versus Radiofrequency,” Circ Arrhythm Electrophysiol., 7(4):734-738 (2014).
van Driel, V.J.H.M. et al., “Low vulnerability of the right phrenic nerve to electroporation ablation,” Heart Rhythm, 12:1838-1844 (2015).
Wittkampf, F.H. et al., “Myocardial Lesion Depth With Circular Electroporation Ablation,” Circ. Arrhythm Electrophysiol., 5(3):581-586 (2012).
Wittkampf, F.H. et al., “Feasibility of Electroporation for the Creation of Pulmonary Vein Ostial Lesions,” J Cardiovasc Electrophysiol, 22(3):302-309 (Mar. 2011).
Office Action for Canadian Application No. 2,881,462, dated Mar. 19, 2019, 5 pages.
Office Action for Japanese Application No. 2018-036714, dated Jan. 16, 2019, 8 pages.
Office Action for U.S. Appl. No. 15/201,983, dated Apr. 3, 2019, 16 pages.
Office Action for U.S. Appl. No. 15/341,523, dated Jan. 29, 2019, 10 pages.
Office Action for U.S. Appl. No. 15/795,075, dated Apr. 10, 2019, 11 pages.
Office Action for U.S. Appl. No. 15/672,916, dated Apr. 9, 2019, 31 pages.
Partial European Search Report for European Application No. 18170210.1, dated Feb. 14, 2019, 13 pages.
Office Action for U.S. Appl. No. 15/970,404, dated Apr. 12, 2019, 20 pages.
Office Action for U.S. Appl. No. 15/917,194, dated Apr. 29, 2019, 10 pages.
Office Action for U.S. Appl. No. 15/795,062, dated May 3, 2019, 21 pages.
International Search Report and Written Opinion for International Application No. PCT/US2019/014226, dated Apr. 29, 2019, 15 pages.
Extended European Search Report for European Application No. 18189811.5, dated May 14, 2019, 7 pages.
International Search Report and Written Opinion for International Application No. PCT/US2019/017322, dated May 10, 2019, 15 pages.
Office Action for U.S. Appl. No. 15/341,512, dated Aug. 1, 2019, 19 pages.
Office Action for U.S. Appl. No. 15/341,523, dated Jul. 30, 2019, 8 pages.
Office Action for U.S. Appl. No. 15/795,075, dated Jul. 31, 2019, 12 pages.
Office Action for U.S. Appl. No. 15/484,969, dated Sep. 4, 2019, 12 pages.
Office Action for U.S. Appl. No. 15/354,475, dated May 23, 2019, 7 pages.
Extended European Search Report for European Application No. 16884132.8, dated Jul. 8, 2019, 7 pages.
Office Action for U.S. Appl. No. 16/416,677, dated Aug. 15, 2019, 8 pages.
Extended European Search Report for European Application No. 17736218.3 dated Aug. 23, 2019, 9 pages.
Office Action for U.S. Appl. No. 16/181,027, dated Sep. 4, 2019, 12 pages.
Office Action for U.S. Appl. No. 16/240,066, dated May 29, 2019, 7 pages.
Extended European Search Report for European Application No. 18170210.1, dated May 17, 2019, 11 pages.
International Search Report and Written Opinion for International Application No. PCT/US2019/030922, dated Sep. 6, 2019, 12 pages.
International Search Report and Written Opinion for International Application No. PCT/US2019/030882, dated Sep. 10, 2019, 17 pages.
Office Action for U.S. Appl. No. 16/405,515, dated Sep. 6, 2019, 9 pages.
International Search Report and Written Opinion for International Application No. PCT/US2019/031135, dated Aug. 5, 2019, 11 pages.
International Search Report and Written Opinion for International Application No. PCT/US2019/028943, dated Sep. 17, 2019, 17 pages.
Extended European Search Report for European Application No. 19182099.2, dated Dec. 13, 2019, 7 pages.
Office Action for Japanese Application No. 2018-036714, dated Nov. 27, 2019, 5 pages.
Office Action for U.S. Appl. No. 15/917,194, dated Dec. 20, 2019, 10 pages.
Office Action for U.S. Appl. No. 15/201,983, dated Nov. 15, 2019, 15 pages.
Office Action for U.S. Appl. No. 15/341,512, dated Nov. 12, 2019, 18 pages.
Office Action for U.S. Appl. No. 15/795,062, dated Nov. 4, 2019, 23 pages.
Office Action for U.S. Appl. No. 16/375,561, dated Oct. 17, 2019, 15 pages.
Office Action for U.S. Appl. No. 15/970,404, dated Nov. 12, 2019, 19 pages.
Office Action for U.S. Appl. No. 16/573,704, dated Dec. 17, 2019, 6 pages.
Office Action for U.S. Appl. No. 16/723,407, dated Mar. 19, 2020, 13 pages.
Tekle, E. et al., “Electroporation by using bipolar oscillating electric field: An improved method for DNA transfection of NIH 3T3 cells,” Proc. Natl. Acad. Sci. USA, vol. 88, pp. 4230-4234, May 1991.
Office Action for U.S. Appl. No. 16/722,650, dated Mar. 25, 2020, 12 pages.
Continuations (1)
Number Date Country
Parent 16573704 Sep 2019 US
Child 16741506 US